Ignite Creation Date:
2025-12-24 @ 11:45 AM
Ignite Modification Date:
2026-04-02 @ 12:46 AM
Study NCT ID:
NCT00661661
Status:
COMPLETED
Last Update Posted:
2015-05-12
First Post:
2008-02-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001172', 'term': 'Arthritis, Rheumatoid'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C479163', 'term': 'tofacitinib'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer, Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Safety observations up to Week 288', 'description': 'The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.', 'eventGroups': [{'id': 'EG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.', 'otherNumAtRisk': 381, 'otherNumAffected': 345, 'seriousNumAtRisk': 381, 'seriousNumAffected': 111}, {'id': 'EG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.', 'otherNumAtRisk': 105, 'otherNumAffected': 101, 'seriousNumAtRisk': 105, 'seriousNumAffected': 28}, {'id': 'EG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total.", 'otherNumAtRisk': 486, 'otherNumAffected': 446, 'seriousNumAtRisk': 486, 'seriousNumAffected': 139}], 'otherEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 25}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 23}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 19}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 34}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 43}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Dental caries', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 39}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 54}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 28}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 33}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 26}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 32}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 24}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 45}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 50}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 39}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 46}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 34}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 45}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Gingivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 17}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 59}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 81}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 37}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 48}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 221}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 72}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 293}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 26}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 33}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Periodontitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 20}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 23}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 36}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 46}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Tinea pedis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 31}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 34}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 40}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 48}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 36}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 48}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 51}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 20}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 71}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ligament sprain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 20}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Road traffic accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 17}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 26}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 23}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Blood cholesterol increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 15}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Low density lipoprotein increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 23}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Lymphocyte count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 29}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 38}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 27}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 19}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Hyperlipidaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 36}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 20}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 56}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 43}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 46}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Rheumatoid arthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 13}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 38}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 48}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 24}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 33}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 23}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Upper respiratory tract inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 34}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 27}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 23}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 40}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 55}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}], 'seriousEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Disseminated intravascular coagulation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Thrombotic thrombocytopenic purpura', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Acute coronary syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Angina pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Prinzmetal angina', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ventricular fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Vertigo positional', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Hyperparathyroidism primary', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cataract', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 3}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Dacryostenosis acquired', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Retinal artery occlusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Retinal detachment', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Colitis ischaemic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Gastric polyps', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Gastric ulcer haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ileus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Inguinal hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Large intestine polyp', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Radicular cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Device material issue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Submandibular mass', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cholecystitis chronic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Liver disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Chronic sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Diverticulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Enteritis infectious', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Enterocolitis infectious', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Enterocolitis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 13}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Herpes zoster disseminated', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Mycobacterium avium complex infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pneumocystis jirovecii pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pneumonia bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pneumonia haemophilus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pneumonia mycoplasmal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pulmonary tuberculosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 5}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Septic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ankle fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Compression fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 3}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Femoral neck fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Femur fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Hand fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Humerus fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Joint dislocation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Patella fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Post procedural haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pubis fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Radius fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Tendon rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 9}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Tibia fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ulna fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Upper limb fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Computerised tomogram thorax abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Arthropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Foot deformity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Intervertebral disc protrusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Joint destruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Kyphosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Lumbar spinal stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 4}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Osteonecrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Periostitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Rheumatoid arthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 4}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Spinal column stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Spondylolisthesis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Acute myeloid leukaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Adenocarcinoma gastric', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Breast cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Colon adenoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Colon cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Colorectal adenocarcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Fallopian tube cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Gastric cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Haemangioma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Liposarcoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Lymphoproliferative disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Malignant ascites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Malignant pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Metastases to liver', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Metastases to lung', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Metastases to lymph nodes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 3}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Metastases to peritoneum', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Neuroendocrine carcinoma of the skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Oesophageal carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ovarian cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ovarian cancer metastatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ovarian germ cell teratoma benign', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': "Paget's disease of nipple", 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Peritoneal neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Small cell lung cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Squamous cell carcinoma of lung', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Transitional cell carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Uterine leiomyoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Carpal tunnel syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cerebral haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cerebral infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cerebral thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Convulsion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cubital tunnel syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'IIIrd nerve paralysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Lacunar infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Loss of consciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Spondylitic myelopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Temporal lobe epilepsy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Transient global amnesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Calculus ureteric', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Glomerulonephritis membranous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Uterine polyp', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Chronic obstructive pulmonary disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Interstitial lung disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Organising pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pleurisy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Skin ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 381, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 486, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n= 378, 105, 483)', 'categories': [{'measurements': [{'value': '80.2', 'groupId': 'OG000'}, {'value': '68.6', 'groupId': 'OG001'}, {'value': '77.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=373, 105, 478)', 'categories': [{'measurements': [{'value': '87.1', 'groupId': 'OG000'}, {'value': '70.5', 'groupId': 'OG001'}, {'value': '83.5', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '90.0', 'groupId': 'OG000'}, {'value': '72.4', 'groupId': 'OG001'}, {'value': '86.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '91.9', 'groupId': 'OG000'}, {'value': '77.1', 'groupId': 'OG001'}, {'value': '88.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '90.8', 'groupId': 'OG000'}, {'value': '85.6', 'groupId': 'OG001'}, {'value': '89.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '94.1', 'groupId': 'OG000'}, {'value': '87.3', 'groupId': 'OG001'}, {'value': '92.5', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '93.7', 'groupId': 'OG000'}, {'value': '88.2', 'groupId': 'OG001'}, {'value': '92.4', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 102, 425)', 'categories': [{'measurements': [{'value': '92.3', 'groupId': 'OG000'}, {'value': '90.2', 'groupId': 'OG001'}, {'value': '91.8', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '92.4', 'groupId': 'OG000'}, {'value': '86.9', 'groupId': 'OG001'}, {'value': '91.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '93.2', 'groupId': 'OG000'}, {'value': '87.0', 'groupId': 'OG001'}, {'value': '91.8', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '92.2', 'groupId': 'OG000'}, {'value': '92.0', 'groupId': 'OG001'}, {'value': '92.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 84, 343)', 'categories': [{'measurements': [{'value': '91.9', 'groupId': 'OG000'}, {'value': '86.9', 'groupId': 'OG001'}, {'value': '90.7', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '91.3', 'groupId': 'OG000'}, {'value': '88.8', 'groupId': 'OG001'}, {'value': '90.7', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=232, 79, 311)', 'categories': [{'measurements': [{'value': '92.2', 'groupId': 'OG000'}, {'value': '84.8', 'groupId': 'OG001'}, {'value': '90.4', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '89.7', 'groupId': 'OG000'}, {'value': '86.8', 'groupId': 'OG001'}, {'value': '89.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 73, 292)', 'categories': [{'measurements': [{'value': '91.3', 'groupId': 'OG000'}, {'value': '84.9', 'groupId': 'OG001'}, {'value': '89.7', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '92.5', 'groupId': 'OG000'}, {'value': '82.9', 'groupId': 'OG001'}, {'value': '90.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '92.8', 'groupId': 'OG000'}, {'value': '86.0', 'groupId': 'OG001'}, {'value': '91.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '92.8', 'groupId': 'OG000'}, {'value': '85.7', 'groupId': 'OG001'}, {'value': '91.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '92.7', 'groupId': 'OG000'}, {'value': '90.0', 'groupId': 'OG001'}, {'value': '92.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '96.1', 'groupId': 'OG000'}, {'value': '84.6', 'groupId': 'OG001'}, {'value': '94.4', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '91.2', 'groupId': 'OG000'}, {'value': '80.0', 'groupId': 'OG001'}, {'value': '90.4', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '93.8', 'groupId': 'OG000'}, {'value': '80.0', 'groupId': 'OG001'}, {'value': '92.9', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '92.3', 'groupId': 'OG000'}, {'value': '80.0', 'groupId': 'OG001'}, {'value': '91.4', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '89.8', 'groupId': 'OG000'}, {'value': '80.0', 'groupId': 'OG001'}, {'value': '89.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=22, 1, 23)', 'categories': [{'measurements': [{'value': '95.5', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '95.7', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'ACR20 response: greater than or equal to (\\>=) 20 percent (%) improvement in tender joint count; \\>=20% improvement in swollen joint count; and \\>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n= 378, 105, 483)', 'categories': [{'measurements': [{'value': '59.5', 'groupId': 'OG000'}, {'value': '36.2', 'groupId': 'OG001'}, {'value': '54.5', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=373, 105, 478)', 'categories': [{'measurements': [{'value': '63.8', 'groupId': 'OG000'}, {'value': '35.2', 'groupId': 'OG001'}, {'value': '57.5', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '70.4', 'groupId': 'OG000'}, {'value': '47.6', 'groupId': 'OG001'}, {'value': '65.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '70.8', 'groupId': 'OG000'}, {'value': '46.7', 'groupId': 'OG001'}, {'value': '65.5', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '76.2', 'groupId': 'OG000'}, {'value': '62.5', 'groupId': 'OG001'}, {'value': '73.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '77.3', 'groupId': 'OG000'}, {'value': '56.9', 'groupId': 'OG001'}, {'value': '72.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '77.3', 'groupId': 'OG000'}, {'value': '59.8', 'groupId': 'OG001'}, {'value': '73.2', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 102, 425)', 'categories': [{'measurements': [{'value': '77.1', 'groupId': 'OG000'}, {'value': '66.7', 'groupId': 'OG001'}, {'value': '74.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '77.8', 'groupId': 'OG000'}, {'value': '74.7', 'groupId': 'OG001'}, {'value': '77.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '78.6', 'groupId': 'OG000'}, {'value': '64.1', 'groupId': 'OG001'}, {'value': '75.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '78.3', 'groupId': 'OG000'}, {'value': '60.9', 'groupId': 'OG001'}, {'value': '74.2', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 84, 343)', 'categories': [{'measurements': [{'value': '79.9', 'groupId': 'OG000'}, {'value': '72.6', 'groupId': 'OG001'}, {'value': '78.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '76.4', 'groupId': 'OG000'}, {'value': '68.8', 'groupId': 'OG001'}, {'value': '74.5', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=232, 79, 311)', 'categories': [{'measurements': [{'value': '77.2', 'groupId': 'OG000'}, {'value': '72.2', 'groupId': 'OG001'}, {'value': '75.9', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '78.1', 'groupId': 'OG000'}, {'value': '69.7', 'groupId': 'OG001'}, {'value': '76.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 73, 292)', 'categories': [{'measurements': [{'value': '79.5', 'groupId': 'OG000'}, {'value': '65.8', 'groupId': 'OG001'}, {'value': '76.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '79.3', 'groupId': 'OG000'}, {'value': '67.1', 'groupId': 'OG001'}, {'value': '76.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '82.2', 'groupId': 'OG000'}, {'value': '71.9', 'groupId': 'OG001'}, {'value': '79.7', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '79.7', 'groupId': 'OG000'}, {'value': '61.9', 'groupId': 'OG001'}, {'value': '75.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '84.4', 'groupId': 'OG000'}, {'value': '80.0', 'groupId': 'OG001'}, {'value': '83.5', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '86.8', 'groupId': 'OG000'}, {'value': '53.8', 'groupId': 'OG001'}, {'value': '82.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '76.5', 'groupId': 'OG000'}, {'value': '80.0', 'groupId': 'OG001'}, {'value': '76.7', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '83.1', 'groupId': 'OG000'}, {'value': '40.0', 'groupId': 'OG001'}, {'value': '80.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '86.2', 'groupId': 'OG000'}, {'value': '40.0', 'groupId': 'OG001'}, {'value': '82.9', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '84.7', 'groupId': 'OG000'}, {'value': '40.0', 'groupId': 'OG001'}, {'value': '81.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=22, 1, 23)', 'categories': [{'measurements': [{'value': '81.8', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '82.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'ACR50 response: greater than or equal to (\\>=) 50 percent (%) improvement in tender joint count; \\>=50% improvement in swollen joint count; and \\>=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n= 378, 105, 483)', 'categories': [{'measurements': [{'value': '37.0', 'groupId': 'OG000'}, {'value': '19.0', 'groupId': 'OG001'}, {'value': '33.1', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=373, 105, 478)', 'categories': [{'measurements': [{'value': '44.8', 'groupId': 'OG000'}, {'value': '20.2', 'groupId': 'OG001'}, {'value': '39.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '47.7', 'groupId': 'OG000'}, {'value': '21.0', 'groupId': 'OG001'}, {'value': '41.8', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '16.2', 'groupId': 'OG001'}, {'value': '42.5', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '54.1', 'groupId': 'OG000'}, {'value': '27.9', 'groupId': 'OG001'}, {'value': '48.2', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '56.6', 'groupId': 'OG000'}, {'value': '24.5', 'groupId': 'OG001'}, {'value': '49.2', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '59.8', 'groupId': 'OG000'}, {'value': '34.3', 'groupId': 'OG001'}, {'value': '53.8', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 102, 425)', 'categories': [{'measurements': [{'value': '59.1', 'groupId': 'OG000'}, {'value': '37.3', 'groupId': 'OG001'}, {'value': '53.9', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '61.9', 'groupId': 'OG000'}, {'value': '38.4', 'groupId': 'OG001'}, {'value': '56.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '60.2', 'groupId': 'OG000'}, {'value': '35.9', 'groupId': 'OG001'}, {'value': '54.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '59.4', 'groupId': 'OG000'}, {'value': '42.5', 'groupId': 'OG001'}, {'value': '55.4', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 84, 343)', 'categories': [{'measurements': [{'value': '60.6', 'groupId': 'OG000'}, {'value': '42.9', 'groupId': 'OG001'}, {'value': '56.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '62.0', 'groupId': 'OG000'}, {'value': '37.5', 'groupId': 'OG001'}, {'value': '55.9', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=232, 79, 311)', 'categories': [{'measurements': [{'value': '60.8', 'groupId': 'OG000'}, {'value': '40.5', 'groupId': 'OG001'}, {'value': '55.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '61.2', 'groupId': 'OG000'}, {'value': '35.5', 'groupId': 'OG001'}, {'value': '54.7', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 73, 292)', 'categories': [{'measurements': [{'value': '61.6', 'groupId': 'OG000'}, {'value': '41.1', 'groupId': 'OG001'}, {'value': '56.5', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '62.9', 'groupId': 'OG000'}, {'value': '41.4', 'groupId': 'OG001'}, {'value': '57.6', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '63.9', 'groupId': 'OG000'}, {'value': '47.4', 'groupId': 'OG001'}, {'value': '59.9', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '63.8', 'groupId': 'OG000'}, {'value': '42.9', 'groupId': 'OG001'}, {'value': '58.9', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '62.4', 'groupId': 'OG000'}, {'value': '56.7', 'groupId': 'OG001'}, {'value': '61.2', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '69.7', 'groupId': 'OG000'}, {'value': '30.8', 'groupId': 'OG001'}, {'value': '64.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '63.2', 'groupId': 'OG000'}, {'value': '20.0', 'groupId': 'OG001'}, {'value': '60.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '69.2', 'groupId': 'OG000'}, {'value': '20.0', 'groupId': 'OG001'}, {'value': '65.7', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '73.8', 'groupId': 'OG000'}, {'value': '20.0', 'groupId': 'OG001'}, {'value': '70.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '71.2', 'groupId': 'OG000'}, {'value': '20.0', 'groupId': 'OG001'}, {'value': '67.2', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=22, 1, 23)', 'categories': [{'measurements': [{'value': '68.2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '65.2', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '66.7', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '66.7', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'ACR70 response: greater than or equal to (\\>=) 70 percent (%) improvement in tender joint count; \\>=70% improvement in swollen joint count; and \\>=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n= 378, 105, 483)', 'categories': [{'measurements': [{'value': '-0.55', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '-0.44', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.53', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=372, 105, 477)', 'categories': [{'measurements': [{'value': '-0.61', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '-0.45', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.57', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '-0.66', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '-0.49', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.62', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '-0.66', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '-0.51', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.63', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '-0.69', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '-0.55', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.65', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '-0.70', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '-0.54', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.66', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '-0.70', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '-0.62', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.68', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 102, 425)', 'categories': [{'measurements': [{'value': '-0.71', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '-0.57', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.67', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '-0.72', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '-0.60', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.69', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '-0.72', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.61', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '-0.69', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '-0.72', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.61', 'spread': '0.06', 'groupId': 'OG001'}, {'value': '-0.69', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 84, 343)', 'categories': [{'measurements': [{'value': '-0.70', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.64', 'spread': '0.06', 'groupId': 'OG001'}, {'value': '-0.69', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '-0.70', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.63', 'spread': '0.06', 'groupId': 'OG001'}, {'value': '-0.68', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=232, 79, 311)', 'categories': [{'measurements': [{'value': '-0.70', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.64', 'spread': '0.06', 'groupId': 'OG001'}, {'value': '-0.68', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '-0.67', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.59', 'spread': '0.07', 'groupId': 'OG001'}, {'value': '-0.65', 'spread': '0.04', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 72, 291)', 'categories': [{'measurements': [{'value': '-0.68', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.62', 'spread': '0.06', 'groupId': 'OG001'}, {'value': '-0.66', 'spread': '0.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '-0.68', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.57', 'spread': '0.07', 'groupId': 'OG001'}, {'value': '-0.65', 'spread': '0.04', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '-0.70', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '-0.63', 'spread': '0.08', 'groupId': 'OG001'}, {'value': '-0.68', 'spread': '0.04', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '-0.69', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '-0.61', 'spread': '0.09', 'groupId': 'OG001'}, {'value': '-0.67', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '-0.67', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.67', 'spread': '0.09', 'groupId': 'OG001'}, {'value': '-0.67', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '-0.62', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.42', 'spread': '0.09', 'groupId': 'OG001'}, {'value': '-0.59', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '-0.62', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.25', 'spread': '0.10', 'groupId': 'OG001'}, {'value': '-0.59', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-0.66', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.33', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-0.64', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-0.68', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-0.25', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-0.65', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '-0.65', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-0.23', 'spread': '0.07', 'groupId': 'OG001'}, {'value': '-0.62', 'spread': '0.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=22, 1, 23)', 'categories': [{'measurements': [{'value': '-0.83', 'spread': '0.11', 'groupId': 'OG000'}, {'value': '-0.63', 'spread': 'NA', 'comment': 'Standard error was not calculated due to one participant data available.', 'groupId': 'OG001'}, {'value': '-0.82', 'spread': '0.11', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '-0.96', 'spread': '0.37', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '-0.96', 'spread': '0.37', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities over past week. Each item scored on 4-point scale, 0 to 3: 0=no difficulty; 1=some difficulty;2=much difficulty; 3=unable to do. Overall score was computed as sum of domain sc ores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n= 378, 105, 483)', 'categories': [{'measurements': [{'value': '-2.60', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-1.94', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-2.45', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=372, 105, 477)', 'categories': [{'measurements': [{'value': '-2.77', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-1.95', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-2.59', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 104, 475)', 'categories': [{'measurements': [{'value': '-2.95', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.14', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-2.77', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '-3.01', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.08', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-2.81', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '-3.12', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.42', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-2.96', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '-3.18', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.54', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-3.03', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '-3.20', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.72', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-3.08', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 101, 424)', 'categories': [{'measurements': [{'value': '-3.25', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.80', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-3.15', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '-3.20', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.83', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-3.11', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '-3.26', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.86', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-3.17', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '-3.21', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.87', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-3.13', 'spread': '0.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 83, 342)', 'categories': [{'measurements': [{'value': '-3.22', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '-2.83', 'spread': '0.15', 'groupId': 'OG001'}, {'value': '-3.12', 'spread': '0.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 79, 321)', 'categories': [{'measurements': [{'value': '-3.24', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '-2.78', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-3.12', 'spread': '0.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=232, 79, 311)', 'categories': [{'measurements': [{'value': '-3.14', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '-2.84', 'spread': '0.15', 'groupId': 'OG001'}, {'value': '-3.07', 'spread': '0.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '-3.17', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '-2.84', 'spread': '0.16', 'groupId': 'OG001'}, {'value': '-3.09', 'spread': '0.08', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=218, 72, 290)', 'categories': [{'measurements': [{'value': '-3.08', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '-2.84', 'spread': '0.16', 'groupId': 'OG001'}, {'value': '-3.02', 'spread': '0.08', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '-3.16', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '-2.87', 'spread': '0.17', 'groupId': 'OG001'}, {'value': '-3.09', 'spread': '0.08', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=178, 56, 234)', 'categories': [{'measurements': [{'value': '-3.21', 'spread': '0.10', 'groupId': 'OG000'}, {'value': '-3.06', 'spread': '0.19', 'groupId': 'OG001'}, {'value': '-3.18', 'spread': '0.09', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '-3.17', 'spread': '0.11', 'groupId': 'OG000'}, {'value': '-3.07', 'spread': '0.19', 'groupId': 'OG001'}, {'value': '-3.15', 'spread': '0.09', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '-3.24', 'spread': '0.12', 'groupId': 'OG000'}, {'value': '-3.35', 'spread': '0.25', 'groupId': 'OG001'}, {'value': '-3.26', 'spread': '0.11', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '-3.20', 'spread': '0.13', 'groupId': 'OG000'}, {'value': '-2.44', 'spread': '0.44', 'groupId': 'OG001'}, {'value': '-3.09', 'spread': '0.13', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '-3.08', 'spread': '0.17', 'groupId': 'OG000'}, {'value': '-2.25', 'spread': '0.58', 'groupId': 'OG001'}, {'value': '-3.02', 'spread': '0.16', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-3.22', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-2.61', 'spread': '0.70', 'groupId': 'OG001'}, {'value': '-3.17', 'spread': '0.14', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-3.33', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-1.81', 'spread': '0.51', 'groupId': 'OG001'}, {'value': '-3.23', 'spread': '0.15', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '-3.32', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-2.09', 'spread': '0.45', 'groupId': 'OG001'}, {'value': '-3.23', 'spread': '0.14', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=21, 1, 22)', 'categories': [{'measurements': [{'value': '-3.34', 'spread': '0.25', 'groupId': 'OG000'}, {'value': '-2.15', 'spread': 'NA', 'comment': 'Standard error was not calculated due to one participant data available.', 'groupId': 'OG001'}, {'value': '-3.29', 'spread': '0.24', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '-2.95', 'spread': '0.51', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '-2.95', 'spread': '0.51', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': "DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour \\[mm/hour\\]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).", 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n= 378, 105, 483)', 'categories': [{'measurements': [{'value': '-2.44', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-1.90', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-2.32', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=372, 105, 477)', 'categories': [{'measurements': [{'value': '-2.55', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-1.90', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-2.41', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '-2.68', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.06', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '-2.55', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '-2.75', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-1.97', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '-2.57', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '-2.85', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.29', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '-2.72', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=337, 102, 439)', 'categories': [{'measurements': [{'value': '-2.92', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.45', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '-2.81', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '-2.92', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.58', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-2.84', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=322, 102, 424)', 'categories': [{'measurements': [{'value': '-2.92', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.60', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '-2.85', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '-2.93', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.61', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '-2.86', 'spread': '0.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '-2.98', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-2.70', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '-2.92', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '-2.95', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.69', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-2.88', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 83, 342)', 'categories': [{'measurements': [{'value': '-2.93', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.64', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-2.86', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '-2.97', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.60', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-2.88', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=231, 79, 310)', 'categories': [{'measurements': [{'value': '-2.89', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '-2.66', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-2.83', 'spread': '0.06', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '-2.90', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '-2.68', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-2.85', 'spread': '0.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 72, 291)', 'categories': [{'measurements': [{'value': '-2.84', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '-2.70', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-2.81', 'spread': '0.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '-2.90', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '-2.68', 'spread': '0.15', 'groupId': 'OG001'}, {'value': '-2.84', 'spread': '0.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '-2.92', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '-2.80', 'spread': '0.17', 'groupId': 'OG001'}, {'value': '-2.89', 'spread': '0.08', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '-2.93', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '-2.84', 'spread': '0.16', 'groupId': 'OG001'}, {'value': '-2.91', 'spread': '0.08', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '-2.95', 'spread': '0.11', 'groupId': 'OG000'}, {'value': '-3.05', 'spread': '0.22', 'groupId': 'OG001'}, {'value': '-2.97', 'spread': '0.10', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '-2.94', 'spread': '0.12', 'groupId': 'OG000'}, {'value': '-2.46', 'spread': '0.34', 'groupId': 'OG001'}, {'value': '-2.87', 'spread': '0.12', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '-2.84', 'spread': '0.17', 'groupId': 'OG000'}, {'value': '-2.38', 'spread': '0.44', 'groupId': 'OG001'}, {'value': '-2.81', 'spread': '0.16', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-2.97', 'spread': '0.13', 'groupId': 'OG000'}, {'value': '-2.36', 'spread': '0.57', 'groupId': 'OG001'}, {'value': '-2.92', 'spread': '0.13', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-3.09', 'spread': '0.14', 'groupId': 'OG000'}, {'value': '-1.89', 'spread': '0.42', 'groupId': 'OG001'}, {'value': '-3.00', 'spread': '0.14', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=58, 5, 63)', 'categories': [{'measurements': [{'value': '-3.13', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-1.86', 'spread': '0.30', 'groupId': 'OG001'}, {'value': '-3.03', 'spread': '0.14', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=22, 1, 23)', 'categories': [{'measurements': [{'value': '-3.24', 'spread': '0.24', 'groupId': 'OG000'}, {'value': '-1.50', 'spread': 'NA', 'comment': 'Standard error was not calculated due to one participant data available.', 'groupId': 'OG001'}, {'value': '-3.16', 'spread': '0.24', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '-2.67', 'spread': '0.27', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '-2.67', 'spread': '0.27', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient Global Assessment of Arthritis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n= 378, 105, 483)', 'categories': [{'measurements': [{'value': '-34.52', 'spread': '1.38', 'groupId': 'OG000'}, {'value': '-25.38', 'spread': '2.43', 'groupId': 'OG001'}, {'value': '-32.54', 'spread': '1.21', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=372, 105, 477)', 'categories': [{'measurements': [{'value': '-37.81', 'spread': '1.36', 'groupId': 'OG000'}, {'value': '-25.34', 'spread': '2.61', 'groupId': 'OG001'}, {'value': '-35.06', 'spread': '1.23', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '-39.61', 'spread': '1.35', 'groupId': 'OG000'}, {'value': '-28.86', 'spread': '2.31', 'groupId': 'OG001'}, {'value': '-37.24', 'spread': '1.19', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '-39.31', 'spread': '1.38', 'groupId': 'OG000'}, {'value': '-27.33', 'spread': '2.23', 'groupId': 'OG001'}, {'value': '-36.67', 'spread': '1.20', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '-40.67', 'spread': '1.39', 'groupId': 'OG000'}, {'value': '-30.75', 'spread': '2.53', 'groupId': 'OG001'}, {'value': '-38.43', 'spread': '1.24', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '-41.70', 'spread': '1.42', 'groupId': 'OG000'}, {'value': '-29.95', 'spread': '2.63', 'groupId': 'OG001'}, {'value': '-38.98', 'spread': '1.27', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '-41.03', 'spread': '1.46', 'groupId': 'OG000'}, {'value': '-32.48', 'spread': '2.56', 'groupId': 'OG001'}, {'value': '-39.02', 'spread': '1.28', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 102, 425)', 'categories': [{'measurements': [{'value': '-41.79', 'spread': '1.44', 'groupId': 'OG000'}, {'value': '-34.33', 'spread': '2.42', 'groupId': 'OG001'}, {'value': '-40.00', 'spread': '1.25', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '-41.30', 'spread': '1.53', 'groupId': 'OG000'}, {'value': '-35.38', 'spread': '2.31', 'groupId': 'OG001'}, {'value': '-39.88', 'spread': '1.29', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '-42.29', 'spread': '1.53', 'groupId': 'OG000'}, {'value': '-35.12', 'spread': '2.63', 'groupId': 'OG001'}, {'value': '-40.65', 'spread': '1.33', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '-41.90', 'spread': '1.62', 'groupId': 'OG000'}, {'value': '-34.98', 'spread': '2.88', 'groupId': 'OG001'}, {'value': '-40.27', 'spread': '1.42', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 84, 343)', 'categories': [{'measurements': [{'value': '-42.47', 'spread': '1.67', 'groupId': 'OG000'}, {'value': '-34.95', 'spread': '2.98', 'groupId': 'OG001'}, {'value': '-40.63', 'spread': '1.46', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '-42.97', 'spread': '1.71', 'groupId': 'OG000'}, {'value': '-35.00', 'spread': '3.05', 'groupId': 'OG001'}, {'value': '-40.99', 'spread': '1.50', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=232, 79, 311)', 'categories': [{'measurements': [{'value': '-42.87', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '-35.05', 'spread': '3.13', 'groupId': 'OG001'}, {'value': '-40.88', 'spread': '1.52', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '-42.48', 'spread': '1.77', 'groupId': 'OG000'}, {'value': '-33.78', 'spread': '3.22', 'groupId': 'OG001'}, {'value': '-40.27', 'spread': '1.57', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 72, 291)', 'categories': [{'measurements': [{'value': '-42.72', 'spread': '1.71', 'groupId': 'OG000'}, {'value': '-32.64', 'spread': '3.13', 'groupId': 'OG001'}, {'value': '-40.22', 'spread': '1.52', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '-43.00', 'spread': '1.72', 'groupId': 'OG000'}, {'value': '-33.61', 'spread': '3.22', 'groupId': 'OG001'}, {'value': '-40.67', 'spread': '1.53', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '-43.22', 'spread': '1.91', 'groupId': 'OG000'}, {'value': '-36.14', 'spread': '3.72', 'groupId': 'OG001'}, {'value': '-41.52', 'spread': '1.71', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '-42.05', 'spread': '2.10', 'groupId': 'OG000'}, {'value': '-34.40', 'spread': '3.95', 'groupId': 'OG001'}, {'value': '-40.27', 'spread': '1.86', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '-42.44', 'spread': '2.36', 'groupId': 'OG000'}, {'value': '-35.73', 'spread': '5.31', 'groupId': 'OG001'}, {'value': '-40.99', 'spread': '2.18', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '-42.04', 'spread': '2.87', 'groupId': 'OG000'}, {'value': '-23.92', 'spread': '9.22', 'groupId': 'OG001'}, {'value': '-39.39', 'spread': '2.86', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '-37.09', 'spread': '2.96', 'groupId': 'OG000'}, {'value': '-17.60', 'spread': '10.66', 'groupId': 'OG001'}, {'value': '-35.75', 'spread': '2.89', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-38.91', 'spread': '2.98', 'groupId': 'OG000'}, {'value': '-18.20', 'spread': '8.36', 'groupId': 'OG001'}, {'value': '-37.43', 'spread': '2.89', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-40.37', 'spread': '2.92', 'groupId': 'OG000'}, {'value': '-7.60', 'spread': '9.17', 'groupId': 'OG001'}, {'value': '-38.03', 'spread': '2.95', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '-37.32', 'spread': '3.69', 'groupId': 'OG000'}, {'value': '-16.20', 'spread': '9.01', 'groupId': 'OG001'}, {'value': '-35.67', 'spread': '3.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=21, 1, 22)', 'categories': [{'measurements': [{'value': '-35.62', 'spread': '6.09', 'groupId': 'OG000'}, {'value': '-10.00', 'spread': 'NA', 'comment': 'Standard error was not calculated due to one participant data available.', 'groupId': 'OG001'}, {'value': '-34.45', 'spread': '5.92', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '-41.67', 'spread': '7.31', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '-41.67', 'spread': '7.31', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Physician Global Assessment of Arthritis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n= 378, 105, 483)', 'categories': [{'measurements': [{'value': '-42.80', 'spread': '1.13', 'groupId': 'OG000'}, {'value': '-33.49', 'spread': '2.01', 'groupId': 'OG001'}, {'value': '-40.78', 'spread': '1.00', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=372, 105, 477)', 'categories': [{'measurements': [{'value': '-46.06', 'spread': '1.08', 'groupId': 'OG000'}, {'value': '-34.91', 'spread': '2.20', 'groupId': 'OG001'}, {'value': '-43.60', 'spread': '0.99', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '-47.34', 'spread': '1.06', 'groupId': 'OG000'}, {'value': '-37.15', 'spread': '2.00', 'groupId': 'OG001'}, {'value': '-45.09', 'spread': '0.95', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '-47.78', 'spread': '1.09', 'groupId': 'OG000'}, {'value': '-36.56', 'spread': '2.33', 'groupId': 'OG001'}, {'value': '-45.30', 'spread': '1.00', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '-48.29', 'spread': '1.07', 'groupId': 'OG000'}, {'value': '-41.26', 'spread': '2.01', 'groupId': 'OG001'}, {'value': '-46.70', 'spread': '0.95', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '-49.28', 'spread': '1.09', 'groupId': 'OG000'}, {'value': '-41.92', 'spread': '2.01', 'groupId': 'OG001'}, {'value': '-47.58', 'spread': '0.97', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '-49.96', 'spread': '1.13', 'groupId': 'OG000'}, {'value': '-45.28', 'spread': '2.08', 'groupId': 'OG001'}, {'value': '-48.86', 'spread': '1.00', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 102, 425)', 'categories': [{'measurements': [{'value': '-49.89', 'spread': '1.14', 'groupId': 'OG000'}, {'value': '-47.01', 'spread': '2.05', 'groupId': 'OG001'}, {'value': '-49.20', 'spread': '1.00', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '-50.03', 'spread': '1.14', 'groupId': 'OG000'}, {'value': '-45.70', 'spread': '1.95', 'groupId': 'OG001'}, {'value': '-48.99', 'spread': '0.99', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '-50.61', 'spread': '1.16', 'groupId': 'OG000'}, {'value': '-46.89', 'spread': '2.17', 'groupId': 'OG001'}, {'value': '-49.75', 'spread': '1.02', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '-49.99', 'spread': '1.28', 'groupId': 'OG000'}, {'value': '-48.16', 'spread': '2.23', 'groupId': 'OG001'}, {'value': '-49.55', 'spread': '1.11', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 83, 342)', 'categories': [{'measurements': [{'value': '-49.62', 'spread': '1.33', 'groupId': 'OG000'}, {'value': '-47.99', 'spread': '2.56', 'groupId': 'OG001'}, {'value': '-49.22', 'spread': '1.18', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '-49.42', 'spread': '1.47', 'groupId': 'OG000'}, {'value': '-47.76', 'spread': '2.39', 'groupId': 'OG001'}, {'value': '-49.01', 'spread': '1.26', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=231, 78, 309)', 'categories': [{'measurements': [{'value': '-49.99', 'spread': '1.41', 'groupId': 'OG000'}, {'value': '-50.19', 'spread': '2.33', 'groupId': 'OG001'}, {'value': '-50.04', 'spread': '1.20', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '-50.80', 'spread': '1.46', 'groupId': 'OG000'}, {'value': '-49.55', 'spread': '2.44', 'groupId': 'OG001'}, {'value': '-50.49', 'spread': '1.25', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 72, 291)', 'categories': [{'measurements': [{'value': '-50.68', 'spread': '1.39', 'groupId': 'OG000'}, {'value': '-49.78', 'spread': '2.58', 'groupId': 'OG001'}, {'value': '-50.46', 'spread': '1.23', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '-51.52', 'spread': '1.45', 'groupId': 'OG000'}, {'value': '-46.33', 'spread': '2.60', 'groupId': 'OG001'}, {'value': '-50.23', 'spread': '1.27', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '-52.20', 'spread': '1.51', 'groupId': 'OG000'}, {'value': '-50.33', 'spread': '2.84', 'groupId': 'OG001'}, {'value': '-51.75', 'spread': '1.33', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '-51.41', 'spread': '1.72', 'groupId': 'OG000'}, {'value': '-50.43', 'spread': '2.98', 'groupId': 'OG001'}, {'value': '-51.18', 'spread': '1.49', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '-51.10', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '-50.97', 'spread': '4.12', 'groupId': 'OG001'}, {'value': '-51.07', 'spread': '1.61', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '-50.91', 'spread': '2.01', 'groupId': 'OG000'}, {'value': '-42.77', 'spread': '6.37', 'groupId': 'OG001'}, {'value': '-49.72', 'spread': '1.96', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=67, 5, 72)', 'categories': [{'measurements': [{'value': '-49.57', 'spread': '2.37', 'groupId': 'OG000'}, {'value': '-33.60', 'spread': '8.88', 'groupId': 'OG001'}, {'value': '-48.46', 'spread': '2.33', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-49.94', 'spread': '2.25', 'groupId': 'OG000'}, {'value': '-34.40', 'spread': '10.30', 'groupId': 'OG001'}, {'value': '-48.83', 'spread': '2.25', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-51.78', 'spread': '2.17', 'groupId': 'OG000'}, {'value': '-31.60', 'spread': '7.92', 'groupId': 'OG001'}, {'value': '-50.34', 'spread': '2.17', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=58, 5, 63)', 'categories': [{'measurements': [{'value': '-52.62', 'spread': '2.36', 'groupId': 'OG000'}, {'value': '-33.80', 'spread': '9.49', 'groupId': 'OG001'}, {'value': '-51.13', 'spread': '2.36', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=21, 1, 22)', 'categories': [{'measurements': [{'value': '-53.05', 'spread': '3.92', 'groupId': 'OG000'}, {'value': '-7.00', 'spread': 'NA', 'comment': 'Standard error was not calculated due to one participant data available.', 'groupId': 'OG001'}, {'value': '-50.95', 'spread': '4.29', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '-37.67', 'spread': '1.33', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '-37.67', 'spread': '1.33', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient Assessment of Arthritis Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n= 378, 105, 483)', 'categories': [{'measurements': [{'value': '-34.23', 'spread': '1.40', 'groupId': 'OG000'}, {'value': '-27.98', 'spread': '2.39', 'groupId': 'OG001'}, {'value': '-32.87', 'spread': '1.22', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=372, 105, 477)', 'categories': [{'measurements': [{'value': '-37.32', 'spread': '1.38', 'groupId': 'OG000'}, {'value': '-27.70', 'spread': '2.61', 'groupId': 'OG001'}, {'value': '-35.20', 'spread': '1.23', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '-39.54', 'spread': '1.34', 'groupId': 'OG000'}, {'value': '-30.69', 'spread': '2.32', 'groupId': 'OG001'}, {'value': '-37.59', 'spread': '1.17', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '-39.34', 'spread': '1.36', 'groupId': 'OG000'}, {'value': '-29.03', 'spread': '2.25', 'groupId': 'OG001'}, {'value': '-37.06', 'spread': '1.18', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '-40.70', 'spread': '1.42', 'groupId': 'OG000'}, {'value': '-33.60', 'spread': '2.50', 'groupId': 'OG001'}, {'value': '-39.10', 'spread': '1.24', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '-41.70', 'spread': '1.45', 'groupId': 'OG000'}, {'value': '-32.71', 'spread': '2.56', 'groupId': 'OG001'}, {'value': '-39.62', 'spread': '1.27', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '-41.98', 'spread': '1.41', 'groupId': 'OG000'}, {'value': '-34.39', 'spread': '2.52', 'groupId': 'OG001'}, {'value': '-40.19', 'spread': '1.24', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 102, 425)', 'categories': [{'measurements': [{'value': '-42.37', 'spread': '1.44', 'groupId': 'OG000'}, {'value': '-36.65', 'spread': '2.36', 'groupId': 'OG001'}, {'value': '-41.00', 'spread': '1.24', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '-41.84', 'spread': '1.51', 'groupId': 'OG000'}, {'value': '-37.41', 'spread': '2.28', 'groupId': 'OG001'}, {'value': '-40.79', 'spread': '1.28', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '-42.49', 'spread': '1.53', 'groupId': 'OG000'}, {'value': '-37.65', 'spread': '2.55', 'groupId': 'OG001'}, {'value': '-41.38', 'spread': '1.32', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '-42.21', 'spread': '1.63', 'groupId': 'OG000'}, {'value': '-38.21', 'spread': '2.87', 'groupId': 'OG001'}, {'value': '-41.27', 'spread': '1.42', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 84, 343)', 'categories': [{'measurements': [{'value': '-42.61', 'spread': '1.68', 'groupId': 'OG000'}, {'value': '-37.99', 'spread': '2.87', 'groupId': 'OG001'}, {'value': '-41.48', 'spread': '1.45', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '-42.44', 'spread': '1.74', 'groupId': 'OG000'}, {'value': '-37.45', 'spread': '2.92', 'groupId': 'OG001'}, {'value': '-41.20', 'spread': '1.50', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=232, 79, 311)', 'categories': [{'measurements': [{'value': '-42.52', 'spread': '1.78', 'groupId': 'OG000'}, {'value': '-37.86', 'spread': '3.04', 'groupId': 'OG001'}, {'value': '-41.33', 'spread': '1.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '-42.05', 'spread': '1.81', 'groupId': 'OG000'}, {'value': '-37.07', 'spread': '3.09', 'groupId': 'OG001'}, {'value': '-40.79', 'spread': '1.56', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 72, 291)', 'categories': [{'measurements': [{'value': '-43.77', 'spread': '1.75', 'groupId': 'OG000'}, {'value': '-36.39', 'spread': '2.89', 'groupId': 'OG001'}, {'value': '-41.94', 'spread': '1.51', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '-43.87', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '-37.96', 'spread': '3.24', 'groupId': 'OG001'}, {'value': '-42.41', 'spread': '1.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '-43.85', 'spread': '1.92', 'groupId': 'OG000'}, {'value': '-40.21', 'spread': '3.51', 'groupId': 'OG001'}, {'value': '-42.97', 'spread': '1.68', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '-42.64', 'spread': '2.22', 'groupId': 'OG000'}, {'value': '-36.67', 'spread': '3.93', 'groupId': 'OG001'}, {'value': '-41.24', 'spread': '1.94', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '-41.11', 'spread': '2.59', 'groupId': 'OG000'}, {'value': '-38.70', 'spread': '5.25', 'groupId': 'OG001'}, {'value': '-40.59', 'spread': '2.32', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '-41.61', 'spread': '2.90', 'groupId': 'OG000'}, {'value': '-30.38', 'spread': '9.30', 'groupId': 'OG001'}, {'value': '-39.97', 'spread': '2.84', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '-37.19', 'spread': '2.96', 'groupId': 'OG000'}, {'value': '-28.40', 'spread': '12.48', 'groupId': 'OG001'}, {'value': '-36.59', 'spread': '2.87', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-36.72', 'spread': '3.08', 'groupId': 'OG000'}, {'value': '-21.20', 'spread': '7.85', 'groupId': 'OG001'}, {'value': '-35.61', 'spread': '2.94', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-38.54', 'spread': '3.19', 'groupId': 'OG000'}, {'value': '-21.20', 'spread': '10.56', 'groupId': 'OG001'}, {'value': '-37.30', 'spread': '3.08', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '-36.80', 'spread': '3.72', 'groupId': 'OG000'}, {'value': '-16.60', 'spread': '11.91', 'groupId': 'OG001'}, {'value': '-35.22', 'spread': '3.60', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=21, 1, 22)', 'categories': [{'measurements': [{'value': '-40.19', 'spread': '5.00', 'groupId': 'OG000'}, {'value': '-44.00', 'spread': 'NA', 'comment': 'Standard error was not calculated due to one participant data available.', 'groupId': 'OG001'}, {'value': '-40.36', 'spread': '4.77', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '-34.67', 'spread': '9.82', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '-34.67', 'spread': '9.82', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Tender/Painful Joint Counts', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n=378, 105, 483)', 'categories': [{'measurements': [{'value': '-11.88', 'spread': '0.48', 'groupId': 'OG000'}, {'value': '-10.17', 'spread': '0.95', 'groupId': 'OG001'}, {'value': '-11.51', 'spread': '0.43', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=373, 105, 478)', 'categories': [{'measurements': [{'value': '-12.13', 'spread': '0.51', 'groupId': 'OG000'}, {'value': '-10.46', 'spread': '0.90', 'groupId': 'OG001'}, {'value': '-11.77', 'spread': '0.45', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '-13.06', 'spread': '0.47', 'groupId': 'OG000'}, {'value': '-10.75', 'spread': '0.96', 'groupId': 'OG001'}, {'value': '-12.55', 'spread': '0.43', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '-13.41', 'spread': '0.47', 'groupId': 'OG000'}, {'value': '-10.74', 'spread': '0.97', 'groupId': 'OG001'}, {'value': '-12.82', 'spread': '0.43', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '-14.02', 'spread': '0.50', 'groupId': 'OG000'}, {'value': '-12.62', 'spread': '0.89', 'groupId': 'OG001'}, {'value': '-13.70', 'spread': '0.44', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '-14.32', 'spread': '0.53', 'groupId': 'OG000'}, {'value': '-13.05', 'spread': '0.94', 'groupId': 'OG001'}, {'value': '-14.03', 'spread': '0.46', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '-14.23', 'spread': '0.53', 'groupId': 'OG000'}, {'value': '-13.43', 'spread': '0.99', 'groupId': 'OG001'}, {'value': '-14.04', 'spread': '0.47', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 102, 425)', 'categories': [{'measurements': [{'value': '-14.23', 'spread': '0.55', 'groupId': 'OG000'}, {'value': '-13.67', 'spread': '0.94', 'groupId': 'OG001'}, {'value': '-14.09', 'spread': '0.48', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '-14.45', 'spread': '0.56', 'groupId': 'OG000'}, {'value': '-14.00', 'spread': '0.96', 'groupId': 'OG001'}, {'value': '-14.34', 'spread': '0.48', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '-14.39', 'spread': '0.56', 'groupId': 'OG000'}, {'value': '-14.04', 'spread': '1.11', 'groupId': 'OG001'}, {'value': '-14.31', 'spread': '0.50', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '-14.44', 'spread': '0.60', 'groupId': 'OG000'}, {'value': '-13.92', 'spread': '1.03', 'groupId': 'OG001'}, {'value': '-14.32', 'spread': '0.52', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 83, 342)', 'categories': [{'measurements': [{'value': '-14.46', 'spread': '0.61', 'groupId': 'OG000'}, {'value': '-13.66', 'spread': '1.14', 'groupId': 'OG001'}, {'value': '-14.26', 'spread': '0.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '-14.67', 'spread': '0.65', 'groupId': 'OG000'}, {'value': '-13.69', 'spread': '1.07', 'groupId': 'OG001'}, {'value': '-14.42', 'spread': '0.55', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=232, 79, 311)', 'categories': [{'measurements': [{'value': '-14.01', 'spread': '0.73', 'groupId': 'OG000'}, {'value': '-13.30', 'spread': '1.33', 'groupId': 'OG001'}, {'value': '-13.83', 'spread': '0.64', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '-14.45', 'spread': '0.68', 'groupId': 'OG000'}, {'value': '-13.83', 'spread': '1.18', 'groupId': 'OG001'}, {'value': '-14.29', 'spread': '0.59', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 72, 291)', 'categories': [{'measurements': [{'value': '-14.24', 'spread': '0.70', 'groupId': 'OG000'}, {'value': '-14.15', 'spread': '1.20', 'groupId': 'OG001'}, {'value': '-14.22', 'spread': '0.61', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '-14.41', 'spread': '0.73', 'groupId': 'OG000'}, {'value': '-14.06', 'spread': '1.25', 'groupId': 'OG001'}, {'value': '-14.33', 'spread': '0.63', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '-14.78', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '-15.18', 'spread': '1.46', 'groupId': 'OG001'}, {'value': '-14.87', 'spread': '0.70', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '-15.01', 'spread': '0.87', 'groupId': 'OG000'}, {'value': '-14.57', 'spread': '1.42', 'groupId': 'OG001'}, {'value': '-14.91', 'spread': '0.74', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '-14.79', 'spread': '0.94', 'groupId': 'OG000'}, {'value': '-15.67', 'spread': '1.93', 'groupId': 'OG001'}, {'value': '-14.98', 'spread': '0.84', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '-14.42', 'spread': '1.04', 'groupId': 'OG000'}, {'value': '-11.38', 'spread': '2.64', 'groupId': 'OG001'}, {'value': '-13.98', 'spread': '0.97', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '-13.78', 'spread': '1.56', 'groupId': 'OG000'}, {'value': '-11.60', 'spread': '5.46', 'groupId': 'OG001'}, {'value': '-13.63', 'spread': '1.49', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-15.11', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '-10.80', 'spread': '4.92', 'groupId': 'OG001'}, {'value': '-14.80', 'spread': '1.12', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-15.34', 'spread': '1.17', 'groupId': 'OG000'}, {'value': '-9.60', 'spread': '4.55', 'groupId': 'OG001'}, {'value': '-14.93', 'spread': '1.14', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '-15.54', 'spread': '1.27', 'groupId': 'OG000'}, {'value': '-9.80', 'spread': '3.95', 'groupId': 'OG001'}, {'value': '-15.09', 'spread': '1.22', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=22, 1, 23)', 'categories': [{'measurements': [{'value': '-17.55', 'spread': '2.55', 'groupId': 'OG000'}, {'value': '-4.00', 'spread': 'NA', 'comment': 'Standard error was not calculated due to one participant data available.', 'groupId': 'OG001'}, {'value': '-16.96', 'spread': '2.51', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '-8.67', 'spread': '1.20', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '-8.67', 'spread': '1.20', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': "This was carried out on 68 joints. Each joint's response to pressure/motion was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).", 'unitOfMeasure': 'Tender/painful joints', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Swollen Joint Counts', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 2 (n=378, 105, 483)', 'categories': [{'measurements': [{'value': '-9.67', 'spread': '0.38', 'groupId': 'OG000'}, {'value': '-8.69', 'spread': '0.74', 'groupId': 'OG001'}, {'value': '-9.46', 'spread': '0.34', 'groupId': 'OG002'}]}]}, {'title': 'Week 4 (n=373, 105, 478)', 'categories': [{'measurements': [{'value': '-10.12', 'spread': '0.42', 'groupId': 'OG000'}, {'value': '-8.54', 'spread': '0.75', 'groupId': 'OG001'}, {'value': '-9.78', 'spread': '0.37', 'groupId': 'OG002'}]}]}, {'title': 'Week 8 (n=371, 105, 476)', 'categories': [{'measurements': [{'value': '-10.90', 'spread': '0.39', 'groupId': 'OG000'}, {'value': '-9.31', 'spread': '0.73', 'groupId': 'OG001'}, {'value': '-10.55', 'spread': '0.35', 'groupId': 'OG002'}]}]}, {'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '-11.18', 'spread': '0.40', 'groupId': 'OG000'}, {'value': '-9.21', 'spread': '0.67', 'groupId': 'OG001'}, {'value': '-10.74', 'spread': '0.35', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '-11.33', 'spread': '0.40', 'groupId': 'OG000'}, {'value': '-10.46', 'spread': '0.72', 'groupId': 'OG001'}, {'value': '-11.13', 'spread': '0.35', 'groupId': 'OG002'}]}]}, {'title': 'Week 36 (n=339, 102, 441)', 'categories': [{'measurements': [{'value': '-11.62', 'spread': '0.43', 'groupId': 'OG000'}, {'value': '-10.75', 'spread': '0.73', 'groupId': 'OG001'}, {'value': '-11.41', 'spread': '0.37', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '-11.76', 'spread': '0.44', 'groupId': 'OG000'}, {'value': '-11.11', 'spread': '0.74', 'groupId': 'OG001'}, {'value': '-11.61', 'spread': '0.38', 'groupId': 'OG002'}]}]}, {'title': 'Week 60 (n=323, 102, 425)', 'categories': [{'measurements': [{'value': '-11.83', 'spread': '0.44', 'groupId': 'OG000'}, {'value': '-10.97', 'spread': '0.76', 'groupId': 'OG001'}, {'value': '-11.62', 'spread': '0.38', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '-12.00', 'spread': '0.46', 'groupId': 'OG000'}, {'value': '-11.38', 'spread': '0.80', 'groupId': 'OG001'}, {'value': '-11.85', 'spread': '0.40', 'groupId': 'OG002'}]}]}, {'title': 'Week 84 (n=309, 92, 401)', 'categories': [{'measurements': [{'value': '-12.08', 'spread': '0.47', 'groupId': 'OG000'}, {'value': '-11.72', 'spread': '0.88', 'groupId': 'OG001'}, {'value': '-12.00', 'spread': '0.41', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '-11.97', 'spread': '0.50', 'groupId': 'OG000'}, {'value': '-11.54', 'spread': '0.84', 'groupId': 'OG001'}, {'value': '-11.87', 'spread': '0.43', 'groupId': 'OG002'}]}]}, {'title': 'Week 108 (n=259, 83, 342)', 'categories': [{'measurements': [{'value': '-11.94', 'spread': '0.52', 'groupId': 'OG000'}, {'value': '-11.60', 'spread': '0.91', 'groupId': 'OG001'}, {'value': '-11.86', 'spread': '0.45', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '-12.09', 'spread': '0.56', 'groupId': 'OG000'}, {'value': '-11.24', 'spread': '0.87', 'groupId': 'OG001'}, {'value': '-11.88', 'spread': '0.47', 'groupId': 'OG002'}]}]}, {'title': 'Week 132 (n=232, 79, 311)', 'categories': [{'measurements': [{'value': '-11.69', 'spread': '0.64', 'groupId': 'OG000'}, {'value': '-11.15', 'spread': '1.16', 'groupId': 'OG001'}, {'value': '-11.55', 'spread': '0.56', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '-11.90', 'spread': '0.61', 'groupId': 'OG000'}, {'value': '-11.74', 'spread': '0.94', 'groupId': 'OG001'}, {'value': '-11.86', 'spread': '0.51', 'groupId': 'OG002'}]}]}, {'title': 'Week 156 (n=219, 72, 291)', 'categories': [{'measurements': [{'value': '-12.07', 'spread': '0.61', 'groupId': 'OG000'}, {'value': '-11.86', 'spread': '1.04', 'groupId': 'OG001'}, {'value': '-12.02', 'spread': '0.52', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '-12.17', 'spread': '0.62', 'groupId': 'OG000'}, {'value': '-11.67', 'spread': '1.05', 'groupId': 'OG001'}, {'value': '-12.05', 'spread': '0.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 180 (n=180, 57, 237)', 'categories': [{'measurements': [{'value': '-12.43', 'spread': '0.70', 'groupId': 'OG000'}, {'value': '-12.26', 'spread': '1.24', 'groupId': 'OG001'}, {'value': '-12.39', 'spread': '0.61', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '-12.36', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '-12.48', 'spread': '1.47', 'groupId': 'OG001'}, {'value': '-12.38', 'spread': '0.69', 'groupId': 'OG002'}]}]}, {'title': 'Week 204 (n=109, 30, 139)', 'categories': [{'measurements': [{'value': '-12.35', 'spread': '0.82', 'groupId': 'OG000'}, {'value': '12.50', 'spread': '1.89', 'groupId': 'OG001'}, {'value': '12.38', 'spread': '0.76', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '-12.34', 'spread': '0.99', 'groupId': 'OG000'}, {'value': '-9.00', 'spread': '2.35', 'groupId': 'OG001'}, {'value': '-11.85', 'spread': '0.91', 'groupId': 'OG002'}]}]}, {'title': 'Week 228 (n=68, 5, 73)', 'categories': [{'measurements': [{'value': '-11.74', 'spread': '1.47', 'groupId': 'OG000'}, {'value': '-11.00', 'spread': '5.09', 'groupId': 'OG001'}, {'value': '-11.68', 'spread': '1.41', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-13.09', 'spread': '1.12', 'groupId': 'OG000'}, {'value': '-11.40', 'spread': '5.48', 'groupId': 'OG001'}, {'value': '-12.97', 'spread': '1.10', 'groupId': 'OG002'}]}]}, {'title': 'Week 252 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '-13.20', 'spread': '1.15', 'groupId': 'OG000'}, {'value': '-10.60', 'spread': '4.70', 'groupId': 'OG001'}, {'value': '-13.01', 'spread': '1.11', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '-13.58', 'spread': '1.24', 'groupId': 'OG000'}, {'value': '-10.00', 'spread': '4.11', 'groupId': 'OG001'}, {'value': '-13.30', 'spread': '1.19', 'groupId': 'OG002'}]}]}, {'title': 'Week 276 (n=22, 1, 23)', 'categories': [{'measurements': [{'value': '-15.32', 'spread': '2.53', 'groupId': 'OG000'}, {'value': '-6.00', 'spread': 'NA', 'comment': 'Standard error was not calculated due to one participant data available.', 'groupId': 'OG001'}, {'value': '-14.91', 'spread': '2.46', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '-8.33', 'spread': '0.88', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '-8.33', 'spread': '0.88', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'Sixty-six (66) joints, the same as those assessed for tenderness/pain except for the right and left hip joints, were assessed for swelling by palpation using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Swollen joints', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Physical Functioning', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '7.87', 'spread': '0.45', 'groupId': 'OG000'}, {'value': '5.94', 'spread': '0.76', 'groupId': 'OG001'}, {'value': '7.45', 'spread': '0.39', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '8.67', 'spread': '0.46', 'groupId': 'OG000'}, {'value': '6.12', 'spread': '1.01', 'groupId': 'OG001'}, {'value': '8.10', 'spread': '0.42', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '9.06', 'spread': '0.48', 'groupId': 'OG000'}, {'value': '6.84', 'spread': '1.05', 'groupId': 'OG001'}, {'value': '8.54', 'spread': '0.45', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '9.10', 'spread': '0.51', 'groupId': 'OG000'}, {'value': '7.61', 'spread': '0.93', 'groupId': 'OG001'}, {'value': '8.74', 'spread': '0.45', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '9.11', 'spread': '0.55', 'groupId': 'OG000'}, {'value': '8.26', 'spread': '0.88', 'groupId': 'OG001'}, {'value': '8.91', 'spread': '0.47', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '9.12', 'spread': '0.57', 'groupId': 'OG000'}, {'value': '8.34', 'spread': '1.09', 'groupId': 'OG001'}, {'value': '8.92', 'spread': '0.51', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '8.85', 'spread': '0.66', 'groupId': 'OG000'}, {'value': '7.57', 'spread': '1.18', 'groupId': 'OG001'}, {'value': '8.53', 'spread': '0.57', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '9.01', 'spread': '0.68', 'groupId': 'OG000'}, {'value': '7.16', 'spread': '1.36', 'groupId': 'OG001'}, {'value': '8.55', 'spread': '0.61', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '9.43', 'spread': '0.78', 'groupId': 'OG000'}, {'value': '8.09', 'spread': '1.25', 'groupId': 'OG001'}, {'value': '9.12', 'spread': '0.66', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '8.78', 'spread': '0.98', 'groupId': 'OG000'}, {'value': '5.04', 'spread': '2.27', 'groupId': 'OG001'}, {'value': '8.23', 'spread': '0.91', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '8.91', 'spread': '1.00', 'groupId': 'OG000'}, {'value': '3.27', 'spread': '1.90', 'groupId': 'OG001'}, {'value': '8.51', 'spread': '0.95', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '8.85', 'spread': '1.08', 'groupId': 'OG000'}, {'value': '1.64', 'spread': '1.98', 'groupId': 'OG001'}, {'value': '8.28', 'spread': '1.03', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '10.23', 'spread': '1.18', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '10.23', 'spread': '1.18', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Physical', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '7.31', 'spread': '0.57', 'groupId': 'OG000'}, {'value': '5.48', 'spread': '1.00', 'groupId': 'OG001'}, {'value': '6.90', 'spread': '0.50', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '8.21', 'spread': '0.59', 'groupId': 'OG000'}, {'value': '6.29', 'spread': '1.06', 'groupId': 'OG001'}, {'value': '7.77', 'spread': '0.51', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '8.38', 'spread': '0.64', 'groupId': 'OG000'}, {'value': '7.77', 'spread': '0.92', 'groupId': 'OG001'}, {'value': '8.23', 'spread': '0.53', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '7.23', 'spread': '0.67', 'groupId': 'OG000'}, {'value': '7.47', 'spread': '1.08', 'groupId': 'OG001'}, {'value': '7.29', 'spread': '0.57', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '7.24', 'spread': '0.70', 'groupId': 'OG000'}, {'value': '8.15', 'spread': '1.16', 'groupId': 'OG001'}, {'value': '7.46', 'spread': '0.60', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '7.69', 'spread': '0.75', 'groupId': 'OG000'}, {'value': '6.77', 'spread': '1.10', 'groupId': 'OG001'}, {'value': '7.46', 'spread': '0.63', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '7.21', 'spread': '0.80', 'groupId': 'OG000'}, {'value': '6.56', 'spread': '1.23', 'groupId': 'OG001'}, {'value': '7.05', 'spread': '0.67', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '7.38', 'spread': '0.77', 'groupId': 'OG000'}, {'value': '5.42', 'spread': '1.41', 'groupId': 'OG001'}, {'value': '6.90', 'spread': '0.68', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '6.59', 'spread': '1.01', 'groupId': 'OG000'}, {'value': '6.70', 'spread': '1.57', 'groupId': 'OG001'}, {'value': '6.61', 'spread': '0.86', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '6.53', 'spread': '1.37', 'groupId': 'OG000'}, {'value': '4.59', 'spread': '2.53', 'groupId': 'OG001'}, {'value': '6.25', 'spread': '1.22', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '6.13', 'spread': '1.56', 'groupId': 'OG000'}, {'value': '-0.48', 'spread': '2.86', 'groupId': 'OG001'}, {'value': '5.66', 'spread': '1.48', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '6.15', 'spread': '1.58', 'groupId': 'OG000'}, {'value': '0.95', 'spread': '2.68', 'groupId': 'OG001'}, {'value': '5.74', 'spread': '1.48', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '22.27', 'spread': '5.22', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '22.27', 'spread': '5.22', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Bodily Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '11.40', 'spread': '0.48', 'groupId': 'OG000'}, {'value': '8.13', 'spread': '0.77', 'groupId': 'OG001'}, {'value': '10.40', 'spread': '0.41', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '11.87', 'spread': '0.50', 'groupId': 'OG000'}, {'value': '9.63', 'spread': '0.79', 'groupId': 'OG001'}, {'value': '11.36', 'spread': '0.43', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '12.19', 'spread': '0.53', 'groupId': 'OG000'}, {'value': '10.65', 'spread': '0.75', 'groupId': 'OG001'}, {'value': '11.83', 'spread': '0.44', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '11.96', 'spread': '0.56', 'groupId': 'OG000'}, {'value': '9.92', 'spread': '0.81', 'groupId': 'OG001'}, {'value': '11.47', 'spread': '0.47', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '11.35', 'spread': '0.59', 'groupId': 'OG000'}, {'value': '11.60', 'spread': '1.04', 'groupId': 'OG001'}, {'value': '11.41', 'spread': '0.51', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '11.98', 'spread': '0.62', 'groupId': 'OG000'}, {'value': '10.42', 'spread': '1.08', 'groupId': 'OG001'}, {'value': '11.60', 'spread': '0.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '11.51', 'spread': '0.68', 'groupId': 'OG000'}, {'value': '11.15', 'spread': '1.04', 'groupId': 'OG001'}, {'value': '11.42', 'spread': '0.57', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '11.82', 'spread': '0.65', 'groupId': 'OG000'}, {'value': '11.07', 'spread': '1.11', 'groupId': 'OG001'}, {'value': '11.63', 'spread': '0.56', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '11.19', 'spread': '0.85', 'groupId': 'OG000'}, {'value': '11.43', 'spread': '1.57', 'groupId': 'OG001'}, {'value': '11.25', 'spread': '0.75', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '12.43', 'spread': '1.03', 'groupId': 'OG000'}, {'value': '8.52', 'spread': '2.37', 'groupId': 'OG001'}, {'value': '11.86', 'spread': '0.95', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '11.34', 'spread': '1.04', 'groupId': 'OG000'}, {'value': '5.25', 'spread': '2.63', 'groupId': 'OG001'}, {'value': '10.90', 'spread': '0.99', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '11.27', 'spread': '1.28', 'groupId': 'OG000'}, {'value': '4.50', 'spread': '2.87', 'groupId': 'OG001'}, {'value': '10.74', 'spread': '1.22', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '7.08', 'spread': '5.60', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '7.08', 'spread': '5.60', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_General Health', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '6.07', 'spread': '0.38', 'groupId': 'OG000'}, {'value': '4.24', 'spread': '0.70', 'groupId': 'OG001'}, {'value': '5.67', 'spread': '0.34', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '6.38', 'spread': '0.39', 'groupId': 'OG000'}, {'value': '5.00', 'spread': '0.58', 'groupId': 'OG001'}, {'value': '6.07', 'spread': '0.33', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '6.40', 'spread': '0.40', 'groupId': 'OG000'}, {'value': '5.20', 'spread': '0.67', 'groupId': 'OG001'}, {'value': '6.12', 'spread': '0.34', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '6.29', 'spread': '0.42', 'groupId': 'OG000'}, {'value': '5.35', 'spread': '0.63', 'groupId': 'OG001'}, {'value': '6.06', 'spread': '0.35', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '6.00', 'spread': '0.45', 'groupId': 'OG000'}, {'value': '4.82', 'spread': '0.73', 'groupId': 'OG001'}, {'value': '5.72', 'spread': '0.38', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '5.86', 'spread': '0.49', 'groupId': 'OG000'}, {'value': '5.36', 'spread': '0.82', 'groupId': 'OG001'}, {'value': '5.74', 'spread': '0.42', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '5.37', 'spread': '0.54', 'groupId': 'OG000'}, {'value': '4.38', 'spread': '0.94', 'groupId': 'OG001'}, {'value': '5.12', 'spread': '0.47', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '5.82', 'spread': '0.53', 'groupId': 'OG000'}, {'value': '3.93', 'spread': '0.87', 'groupId': 'OG001'}, {'value': '5.35', 'spread': '0.46', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '4.72', 'spread': '0.61', 'groupId': 'OG000'}, {'value': '4.10', 'spread': '1.05', 'groupId': 'OG001'}, {'value': '4.57', 'spread': '0.53', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '3.73', 'spread': '0.87', 'groupId': 'OG000'}, {'value': '1.59', 'spread': '1.31', 'groupId': 'OG001'}, {'value': '3.42', 'spread': '0.77', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '4.39', 'spread': '0.96', 'groupId': 'OG000'}, {'value': '-1.50', 'spread': '1.90', 'groupId': 'OG001'}, {'value': '3.97', 'spread': '0.92', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '4.12', 'spread': '1.01', 'groupId': 'OG000'}, {'value': '-1.03', 'spread': '2.17', 'groupId': 'OG001'}, {'value': '3.72', 'spread': '0.96', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '-0.94', 'spread': '4.23', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '-0.94', 'spread': '4.23', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Vitality', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '7.37', 'spread': '0.59', 'groupId': 'OG000'}, {'value': '6.61', 'spread': '0.90', 'groupId': 'OG001'}, {'value': '7.20', 'spread': '0.50', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '7.24', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '6.25', 'spread': '0.97', 'groupId': 'OG001'}, {'value': '7.02', 'spread': '0.50', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '6.83', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '7.22', 'spread': '0.89', 'groupId': 'OG001'}, {'value': '6.92', 'spread': '0.49', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '7.02', 'spread': '0.61', 'groupId': 'OG000'}, {'value': '6.44', 'spread': '0.98', 'groupId': 'OG001'}, {'value': '6.88', 'spread': '0.52', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '6.78', 'spread': '0.61', 'groupId': 'OG000'}, {'value': '6.19', 'spread': '1.11', 'groupId': 'OG001'}, {'value': '6.64', 'spread': '0.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '6.49', 'spread': '0.70', 'groupId': 'OG000'}, {'value': '6.96', 'spread': '1.26', 'groupId': 'OG001'}, {'value': '6.61', 'spread': '0.61', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '6.27', 'spread': '0.75', 'groupId': 'OG000'}, {'value': '5.51', 'spread': '1.15', 'groupId': 'OG001'}, {'value': '6.08', 'spread': '0.63', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '6.58', 'spread': '0.72', 'groupId': 'OG000'}, {'value': '4.75', 'spread': '1.27', 'groupId': 'OG001'}, {'value': '6.12', 'spread': '0.63', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '5.40', 'spread': '0.92', 'groupId': 'OG000'}, {'value': '5.70', 'spread': '1.62', 'groupId': 'OG001'}, {'value': '5.47', 'spread': '0.80', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '5.04', 'spread': '1.18', 'groupId': 'OG000'}, {'value': '5.30', 'spread': '2.47', 'groupId': 'OG001'}, {'value': '5.08', 'spread': '1.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '5.11', 'spread': '1.21', 'groupId': 'OG000'}, {'value': '-0.60', 'spread': '3.05', 'groupId': 'OG001'}, {'value': '4.70', 'spread': '1.15', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '4.72', 'spread': '1.17', 'groupId': 'OG000'}, {'value': '-1.80', 'spread': '3.36', 'groupId': 'OG001'}, {'value': '4.21', 'spread': '1.13', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '14.97', 'spread': '8.64', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '14.97', 'spread': '8.64', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Social Functioning', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '4.99', 'spread': '0.60', 'groupId': 'OG000'}, {'value': '5.17', 'spread': '1.09', 'groupId': 'OG001'}, {'value': '5.03', 'spread': '0.52', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '5.57', 'spread': '0.62', 'groupId': 'OG000'}, {'value': '4.96', 'spread': '1.25', 'groupId': 'OG001'}, {'value': '5.44', 'spread': '0.56', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '5.28', 'spread': '0.64', 'groupId': 'OG000'}, {'value': '5.27', 'spread': '1.14', 'groupId': 'OG001'}, {'value': '5.28', 'spread': '0.55', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '4.81', 'spread': '0.64', 'groupId': 'OG000'}, {'value': '4.78', 'spread': '1.31', 'groupId': 'OG001'}, {'value': '4.81', 'spread': '0.58', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '4.88', 'spread': '0.67', 'groupId': 'OG000'}, {'value': '6.43', 'spread': '1.19', 'groupId': 'OG001'}, {'value': '5.25', 'spread': '0.58', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '5.20', 'spread': '0.76', 'groupId': 'OG000'}, {'value': '5.98', 'spread': '1.11', 'groupId': 'OG001'}, {'value': '5.39', 'spread': '0.63', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '5.23', 'spread': '0.77', 'groupId': 'OG000'}, {'value': '3.33', 'spread': '1.39', 'groupId': 'OG001'}, {'value': '4.75', 'spread': '0.67', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '4.72', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '3.84', 'spread': '1.43', 'groupId': 'OG001'}, {'value': '4.50', 'spread': '0.69', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '4.56', 'spread': '0.96', 'groupId': 'OG000'}, {'value': '5.63', 'spread': '1.36', 'groupId': 'OG001'}, {'value': '4.81', 'spread': '0.80', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '4.53', 'spread': '1.23', 'groupId': 'OG000'}, {'value': '3.31', 'spread': '2.48', 'groupId': 'OG001'}, {'value': '4.35', 'spread': '1.10', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '4.88', 'spread': '1.41', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG001'}, {'value': '4.53', 'spread': '1.32', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '4.47', 'spread': '1.45', 'groupId': 'OG000'}, {'value': '-2.15', 'spread': '2.15', 'groupId': 'OG001'}, {'value': '3.95', 'spread': '1.37', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '14.34', 'spread': '9.49', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '14.34', 'spread': '9.49', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Emotional', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '6.65', 'spread': '0.65', 'groupId': 'OG000'}, {'value': '4.98', 'spread': '1.19', 'groupId': 'OG001'}, {'value': '6.28', 'spread': '0.57', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '6.88', 'spread': '0.73', 'groupId': 'OG000'}, {'value': '4.40', 'spread': '1.41', 'groupId': 'OG001'}, {'value': '6.32', 'spread': '0.65', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '7.26', 'spread': '0.75', 'groupId': 'OG000'}, {'value': '5.49', 'spread': '1.29', 'groupId': 'OG001'}, {'value': '6.85', 'spread': '0.65', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '6.02', 'spread': '0.78', 'groupId': 'OG000'}, {'value': '5.54', 'spread': '1.28', 'groupId': 'OG001'}, {'value': '5.91', 'spread': '0.67', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '6.04', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '5.96', 'spread': '1.43', 'groupId': 'OG001'}, {'value': '6.02', 'spread': '0.69', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '5.68', 'spread': '0.90', 'groupId': 'OG000'}, {'value': '3.98', 'spread': '1.40', 'groupId': 'OG001'}, {'value': '5.26', 'spread': '0.76', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '5.39', 'spread': '0.96', 'groupId': 'OG000'}, {'value': '3.74', 'spread': '1.56', 'groupId': 'OG001'}, {'value': '4.97', 'spread': '0.82', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '5.90', 'spread': '0.89', 'groupId': 'OG000'}, {'value': '4.43', 'spread': '1.49', 'groupId': 'OG001'}, {'value': '5.54', 'spread': '0.76', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '4.31', 'spread': '1.23', 'groupId': 'OG000'}, {'value': '4.42', 'spread': '1.91', 'groupId': 'OG001'}, {'value': '4.33', 'spread': '1.04', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '4.33', 'spread': '1.55', 'groupId': 'OG000'}, {'value': '3.49', 'spread': '2.76', 'groupId': 'OG001'}, {'value': '4.21', 'spread': '1.38', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '4.72', 'spread': '1.66', 'groupId': 'OG000'}, {'value': '-0.76', 'spread': '4.22', 'groupId': 'OG001'}, {'value': '4.33', 'spread': '1.58', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '5.07', 'spread': '1.74', 'groupId': 'OG000'}, {'value': '-0.76', 'spread': '4.22', 'groupId': 'OG001'}, {'value': '4.61', 'spread': '1.64', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '22.71', 'spread': '5.78', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '22.71', 'spread': '5.78', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Mental Health', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '6.27', 'spread': '0.63', 'groupId': 'OG000'}, {'value': '5.38', 'spread': '1.04', 'groupId': 'OG001'}, {'value': '6.08', 'spread': '0.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '6.22', 'spread': '0.65', 'groupId': 'OG000'}, {'value': '3.84', 'spread': '1.17', 'groupId': 'OG001'}, {'value': '5.69', 'spread': '0.57', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '5.73', 'spread': '0.64', 'groupId': 'OG000'}, {'value': '5.35', 'spread': '1.02', 'groupId': 'OG001'}, {'value': '5.64', 'spread': '0.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '4.77', 'spread': '0.70', 'groupId': 'OG000'}, {'value': '5.48', 'spread': '1.04', 'groupId': 'OG001'}, {'value': '4.94', 'spread': '0.59', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '5.23', 'spread': '0.68', 'groupId': 'OG000'}, {'value': '5.89', 'spread': '1.14', 'groupId': 'OG001'}, {'value': '5.38', 'spread': '0.59', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '5.56', 'spread': '0.77', 'groupId': 'OG000'}, {'value': '5.26', 'spread': '1.31', 'groupId': 'OG001'}, {'value': '5.49', 'spread': '0.67', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '5.10', 'spread': '0.84', 'groupId': 'OG000'}, {'value': '4.37', 'spread': '1.34', 'groupId': 'OG001'}, {'value': '4.91', 'spread': '0.71', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '5.12', 'spread': '0.76', 'groupId': 'OG000'}, {'value': '3.76', 'spread': '1.29', 'groupId': 'OG001'}, {'value': '4.79', 'spread': '0.66', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '3.77', 'spread': '0.93', 'groupId': 'OG000'}, {'value': '5.21', 'spread': '1.75', 'groupId': 'OG001'}, {'value': '4.11', 'spread': '0.82', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '2.66', 'spread': '1.21', 'groupId': 'OG000'}, {'value': '4.26', 'spread': '3.04', 'groupId': 'OG001'}, {'value': '2.89', 'spread': '1.12', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '3.75', 'spread': '1.20', 'groupId': 'OG000'}, {'value': '3.32', 'spread': '2.04', 'groupId': 'OG001'}, {'value': '3.72', 'spread': '1.12', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '4.18', 'spread': '1.34', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '1.75', 'groupId': 'OG001'}, {'value': '3.85', 'spread': '1.25', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '14.78', 'spread': '7.56', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '14.78', 'spread': '7.56', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Physical', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '8.44', 'spread': '0.39', 'groupId': 'OG000'}, {'value': '6.09', 'spread': '0.68', 'groupId': 'OG001'}, {'value': '7.92', 'spread': '0.34', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '9.39', 'spread': '0.38', 'groupId': 'OG000'}, {'value': '7.56', 'spread': '0.70', 'groupId': 'OG001'}, {'value': '8.98', 'spread': '0.34', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '9.75', 'spread': '0.43', 'groupId': 'OG000'}, {'value': '8.24', 'spread': '0.72', 'groupId': 'OG001'}, {'value': '9.39', 'spread': '0.37', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '9.72', 'spread': '0.43', 'groupId': 'OG000'}, {'value': '8.21', 'spread': '0.76', 'groupId': 'OG001'}, {'value': '9.36', 'spread': '0.37', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '9.35', 'spread': '0.48', 'groupId': 'OG000'}, {'value': '8.93', 'spread': '0.77', 'groupId': 'OG001'}, {'value': '9.25', 'spread': '0.41', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '9.66', 'spread': '0.49', 'groupId': 'OG000'}, {'value': '8.79', 'spread': '0.92', 'groupId': 'OG001'}, {'value': '9.45', 'spread': '0.43', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '9.26', 'spread': '0.54', 'groupId': 'OG000'}, {'value': '8.60', 'spread': '0.92', 'groupId': 'OG001'}, {'value': '9.09', 'spread': '0.47', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '9.51', 'spread': '0.54', 'groupId': 'OG000'}, {'value': '7.86', 'spread': '1.03', 'groupId': 'OG001'}, {'value': '9.10', 'spread': '0.48', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '9.51', 'spread': '0.65', 'groupId': 'OG000'}, {'value': '8.56', 'spread': '1.18', 'groupId': 'OG001'}, {'value': '9.29', 'spread': '0.57', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '9.59', 'spread': '0.88', 'groupId': 'OG000'}, {'value': '5.37', 'spread': '1.93', 'groupId': 'OG001'}, {'value': '8.97', 'spread': '0.82', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '9.00', 'spread': '0.93', 'groupId': 'OG000'}, {'value': '1.91', 'spread': '2.87', 'groupId': 'OG001'}, {'value': '8.49', 'spread': '0.91', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '8.72', 'spread': '1.03', 'groupId': 'OG000'}, {'value': '2.31', 'spread': '2.27', 'groupId': 'OG001'}, {'value': '8.22', 'spread': '0.99', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '6.87', 'spread': '1.88', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '6.87', 'spread': '1.88', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Mental', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 12 (n=370, 105, 475)', 'categories': [{'measurements': [{'value': '5.13', 'spread': '0.63', 'groupId': 'OG000'}, {'value': '4.82', 'spread': '1.01', 'groupId': 'OG001'}, {'value': '5.06', 'spread': '0.54', 'groupId': 'OG002'}]}]}, {'title': 'Week 24 (n=357, 104, 461)', 'categories': [{'measurements': [{'value': '4.95', 'spread': '0.67', 'groupId': 'OG000'}, {'value': '3.38', 'spread': '1.26', 'groupId': 'OG001'}, {'value': '4.60', 'spread': '0.59', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=331, 102, 433)', 'categories': [{'measurements': [{'value': '4.56', 'spread': '0.66', 'groupId': 'OG000'}, {'value': '4.45', 'spread': '1.06', 'groupId': 'OG001'}, {'value': '4.54', 'spread': '0.56', 'groupId': 'OG002'}]}]}, {'title': 'Week 72 (n=315, 99, 414)', 'categories': [{'measurements': [{'value': '3.63', 'spread': '0.69', 'groupId': 'OG000'}, {'value': '4.15', 'spread': '1.14', 'groupId': 'OG001'}, {'value': '3.75', 'spread': '0.59', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=281, 87, 368)', 'categories': [{'measurements': [{'value': '3.88', 'spread': '0.68', 'groupId': 'OG000'}, {'value': '4.53', 'spread': '1.25', 'groupId': 'OG001'}, {'value': '4.03', 'spread': '0.60', 'groupId': 'OG002'}]}]}, {'title': 'Week 120 (n=242, 80, 322)', 'categories': [{'measurements': [{'value': '3.79', 'spread': '0.80', 'groupId': 'OG000'}, {'value': '3.68', 'spread': '1.37', 'groupId': 'OG001'}, {'value': '3.76', 'spread': '0.69', 'groupId': 'OG002'}]}]}, {'title': 'Week 144 (n=224, 76, 300)', 'categories': [{'measurements': [{'value': '3.57', 'spread': '0.84', 'groupId': 'OG000'}, {'value': '2.24', 'spread': '1.40', 'groupId': 'OG001'}, {'value': '3.23', 'spread': '0.72', 'groupId': 'OG002'}]}]}, {'title': 'Week 168 (n=213, 70, 283)', 'categories': [{'measurements': [{'value': '3.64', 'spread': '0.80', 'groupId': 'OG000'}, {'value': '2.45', 'spread': '1.41', 'groupId': 'OG001'}, {'value': '3.35', 'spread': '0.70', 'groupId': 'OG002'}]}]}, {'title': 'Week 192 (n=138, 42, 180)', 'categories': [{'measurements': [{'value': '2.05', 'spread': '0.99', 'groupId': 'OG000'}, {'value': '3.44', 'spread': '1.80', 'groupId': 'OG001'}, {'value': '2.38', 'spread': '0.86', 'groupId': 'OG002'}]}]}, {'title': 'Week 216 (n=76, 13, 89)', 'categories': [{'measurements': [{'value': '1.49', 'spread': '1.29', 'groupId': 'OG000'}, {'value': '3.14', 'spread': '3.04', 'groupId': 'OG001'}, {'value': '1.73', 'spread': '1.18', 'groupId': 'OG002'}]}]}, {'title': 'Week 240 (n=65, 5, 70)', 'categories': [{'measurements': [{'value': '2.41', 'spread': '1.27', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '1.81', 'groupId': 'OG001'}, {'value': '2.23', 'spread': '1.19', 'groupId': 'OG002'}]}]}, {'title': 'Week 264 (n=59, 5, 64)', 'categories': [{'measurements': [{'value': '2.59', 'spread': '1.42', 'groupId': 'OG000'}, {'value': '-2.25', 'spread': '1.41', 'groupId': 'OG001'}, {'value': '2.21', 'spread': '1.32', 'groupId': 'OG002'}]}]}, {'title': 'Week 288 (n=3, 0, 3)', 'categories': [{'measurements': [{'value': '18.64', 'spread': '4.01', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Mean and standard error were not calculated because no data were available.', 'groupId': 'OG001'}, {'value': '18.64', 'spread': '4.01', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): All participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'SECONDARY', 'title': 'Change From Month 24 in Study A3921044 in Modified Total Sharp Score (mTSS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '82', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Week 24 (n=69, 7, 76)', 'categories': [{'measurements': [{'value': '0.17', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '0.50', 'spread': '0.22', 'groupId': 'OG001'}, {'value': '0.20', 'spread': '0.08', 'groupId': 'OG002'}]}]}, {'title': 'Week 48 (n=64, 7, 71)', 'categories': [{'measurements': [{'value': '0.27', 'spread': '0.17', 'groupId': 'OG000'}, {'value': '1.75', 'spread': '1.16', 'groupId': 'OG001'}, {'value': '0.41', 'spread': '0.19', 'groupId': 'OG002'}]}]}, {'title': 'Week 96 (n=39, 1, 40)', 'categories': [{'measurements': [{'value': '0.40', 'spread': '0.21', 'groupId': 'OG000'}, {'value': '1.00', 'spread': 'NA', 'comment': 'Standard error was not calculated because there was one participant data.', 'groupId': 'OG001'}, {'value': '0.42', 'spread': '0.20', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'First visit in the study (Month 24 in Study A3921044), Weeks 24, 48, and 96', 'description': 'mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented potential improvement. Month 24 (the final visit) in Study A3921044 was taken as the first visit in current study.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Participants who had completed Study A3921044 among all participants who received at least 1 dose of study medication in current study. No imputation was used (observed data).'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '486', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'OG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'OG002', 'title': 'Total', 'description': "All subjects were assigned oral CP-690,550 5 mg tablets twice a day at baseline visit. Dose flexibility (increasing from 5 mg BID to 10 mg BID, reducing from 10 mg BID to 5 mg BID, or temporary discontinuation) during study was allowed in consideration for the risks and benefits to the patient's condition. Data was summarized in three reporting groups including CP-690,550 5 mg BID, CP-690,550 10 mg BID and Total."}], 'classes': [{'title': 'Number of participants with AEs (including SAEs)', 'categories': [{'measurements': [{'value': '371', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '476', 'groupId': 'OG002'}]}]}, {'title': 'Number of participants with SAEs', 'categories': [{'measurements': [{'value': '111', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '139', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Week 288', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to the last participants visit in the study. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for safety evaluation.', 'unitOfMeasure': 'Particiants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set: all participants who received at least 1 dose of study medication in current study.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'FG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '382'}, {'groupId': 'FG001', 'numSubjects': '105'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '242'}, {'groupId': 'FG001', 'numSubjects': '66'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '140'}, {'groupId': 'FG001', 'numSubjects': '39'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '99'}, {'groupId': 'FG001', 'numSubjects': '24'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '5'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '22'}, {'groupId': 'FG001', 'numSubjects': '7'}]}, {'type': 'Not assigned treatment', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'Participants received study drug (CP-690,550 or placebo) in the precedent study A3921039 (NCT00603512) for 12 weeks, A3921040 (NCT00687193) for 12 weeks, or A3921044 (NCT00847613) for 2 years.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '381', 'groupId': 'BG000'}, {'value': '105', 'groupId': 'BG001'}, {'value': '486', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'CP-690,550 5 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for less than 84 days in total within the current study (A3921041) were grouped into CP-690,550 5 mg BID.'}, {'id': 'BG001', 'title': 'CP-690,550 10 mg BID', 'description': 'CP-690,550 5 milligram (mg) tablet orally twice daily (BID). After Week 12, the dose could be changed 5 mg BID or 10 mg BID based on investigator discretion. This study was continued until CP-690,550 was commercially supplied to participants at the sites. Participants who were exposed to 10 mg BID for more than or equal to 84 days in total within the long-term safety study (A3921041) were grouped into CP-690,550 10 mg BID.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '53.5', 'spread': '11.2', 'groupId': 'BG000'}, {'value': '49.3', 'spread': '11.7', 'groupId': 'BG001'}, {'value': '52.6', 'spread': '11.4', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '318', 'groupId': 'BG000'}, {'value': '86', 'groupId': 'BG001'}, {'value': '404', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '63', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '82', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 487}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-04'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-04', 'completionDateStruct': {'date': '2013-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-04-23', 'studyFirstSubmitDate': '2008-02-07', 'resultsFirstSubmitDate': '2015-02-17', 'studyFirstSubmitQcDate': '2008-04-15', 'lastUpdatePostDateStruct': {'date': '2015-05-12', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2015-04-23', 'studyFirstPostDateStruct': {'date': '2008-04-18', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2015-05-12', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)', 'timeFrame': 'Baseline up to Week 288', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to the last participants visit in the study. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for safety evaluation.'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response', 'timeFrame': 'Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'ACR20 response: greater than or equal to (\\>=) 20 percent (%) improvement in tender joint count; \\>=20% improvement in swollen joint count; and \\>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'timeFrame': 'Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'ACR50 response: greater than or equal to (\\>=) 50 percent (%) improvement in tender joint count; \\>=50% improvement in swollen joint count; and \\>=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'timeFrame': 'Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'ACR70 response: greater than or equal to (\\>=) 70 percent (%) improvement in tender joint count; \\>=70% improvement in swollen joint count; and \\>=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities over past week. Each item scored on 4-point scale, 0 to 3: 0=no difficulty; 1=some difficulty;2=much difficulty; 3=unable to do. Overall score was computed as sum of domain sc ores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': "DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour \\[mm/hour\\]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS)."}, {'measure': 'Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in Patient Global Assessment of Arthritis', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in Physician Global Assessment of Arthritis', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in Patient Assessment of Arthritis Pain', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in Tender/Painful Joint Counts', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': "This was carried out on 68 joints. Each joint's response to pressure/motion was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS)."}, {'measure': 'Change From Baseline in Swollen Joint Counts', 'timeFrame': 'Baseline, Weeks 2, 4,8,12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276 and 288', 'description': 'Sixty-six (66) joints, the same as those assessed for tenderness/pain except for the right and left hip joints, were assessed for swelling by palpation using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial joints). The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Physical Functioning', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Physical', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Bodily Pain', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_General Health', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Vitality', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Social Functioning', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Role Emotional', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Domain Score_Mental Health', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Physical', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Component Score_Mental', 'timeFrame': 'Baseline, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, and 288', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning. The baseline data of Study A3921039, A3921040 or A3921044 were used as baseline data for efficacy evaluations except for Modified Total Sharp Score (mTSS).'}, {'measure': 'Change From Month 24 in Study A3921044 in Modified Total Sharp Score (mTSS)', 'timeFrame': 'First visit in the study (Month 24 in Study A3921044), Weeks 24, 48, and 96', 'description': 'mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented potential improvement. Month 24 (the final visit) in Study A3921044 was taken as the first visit in current study.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Long term open label study in Japan', 'CP-690', '550', 'tofacitinib'], 'conditions': ['Rheumatoid Arthritis']}, 'referencesModule': {'references': [{'pmid': '38883150', 'type': 'DERIVED', 'citation': 'Pope J, Finckh A, Silva-Fernandez L, Mandl P, Fan H, Rivas JL, Valderrama M, Montoro M. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention. Open Access Rheumatol. 2024 Jun 11;16:115-126. doi: 10.2147/OARRR.S446431. eCollection 2024.'}, {'pmid': '38854417', 'type': 'DERIVED', 'citation': 'Curtis JR, Wollenhaupt J, Tas SW, Chatzidionysiou K, Wang L, Roberts K, Tsekouras V. Determinants of tofacitinib discontinuation in adult patients with rheumatoid arthritis during long-term extension studies up to 9.5 years. Rheumatol Adv Pract. 2024 May 11;8(2):rkae063. doi: 10.1093/rap/rkae063. eCollection 2024.'}, {'pmid': '37453736', 'type': 'DERIVED', 'citation': 'Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.'}, {'pmid': '36931693', 'type': 'DERIVED', 'citation': 'Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.'}, {'pmid': '36601090', 'type': 'DERIVED', 'citation': 'Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.'}, {'pmid': '36600185', 'type': 'DERIVED', 'citation': 'Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.'}, {'pmid': '36526796', 'type': 'DERIVED', 'citation': 'Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.'}, {'pmid': '34870800', 'type': 'DERIVED', 'citation': 'Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.'}, {'pmid': '33127856', 'type': 'DERIVED', 'citation': 'Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.'}, {'pmid': '33057725', 'type': 'DERIVED', 'citation': 'van der Heijde D, Landewe RBM, Wollenhaupt J, Strengholt S, Terry K, Kwok K, Wang L, Cohen S. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. Rheumatology (Oxford). 2021 Apr 6;60(4):1708-1716. doi: 10.1093/rheumatology/keaa476.'}, {'pmid': '32816215', 'type': 'DERIVED', 'citation': 'Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20.'}, {'pmid': '29435359', 'type': 'DERIVED', 'citation': 'Fleischmann R, Wollenhaupt J, Takiya L, Maniccia A, Kwok K, Wang L, van Vollenhoven RF. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open. 2017 Dec 18;3(2):e000491. doi: 10.1136/rmdopen-2017-000491. eCollection 2017.'}, {'pmid': '29417430', 'type': 'DERIVED', 'citation': 'Fleischmann R, Wollenhaupt J, Cohen S, Wang L, Fan H, Bandi V, Andrews J, Takiya L, Bananis E, Weinblatt ME. Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatol Ther. 2018 Jun;5(1):203-214. doi: 10.1007/s40744-018-0093-7. Epub 2018 Feb 7.'}, {'pmid': '28143815', 'type': 'DERIVED', 'citation': 'Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.'}, {'pmid': '26818974', 'type': 'DERIVED', 'citation': 'Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, Zwillich S. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016 Jan 28;18:34. doi: 10.1186/s13075-016-0932-2.'}, {'pmid': '25047021', 'type': 'DERIVED', 'citation': 'Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779.'}], 'seeAlsoLinks': [{'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921041&StudyName=Long-Term%2C%20Open-Label%20Study%20Of%20CP-690%2C550%20For%20Treatment%20Of%20Rheumatoid%20Arthritis%20In%20Japan', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are only eligible for this study after they have completed participation in another "qualifying" study of CP-690,550.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Subjects who have completed their participation in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis\n\nExclusion Criteria:\n\n* Serious medical conditions that would make treatment with CP-690,550 potentially unsafe'}, 'identificationModule': {'nctId': 'NCT00661661', 'briefTitle': 'Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A Long-term, Open-label Study Of Cp-690,550 to Confirm The Safety Following Long Term Administration Of Cp-690,550 In The Treatment Of Rheumatoid Arthritis', 'orgStudyIdInfo': {'id': 'A3921041'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'CP-690,550', 'interventionNames': ['Drug: CP-690,550']}], 'interventions': [{'name': 'CP-690,550', 'type': 'DRUG', 'description': '5 mg BID up to 10 mg BID until launch', 'armGroupLabels': ['CP-690,550']}]}, 'contactsLocationsModule': {'locations': [{'zip': '460-0001', 'city': 'Nagoya', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': 'National hospital Organization Nagoya Medical Center', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '466-8560', 'city': 'Nagoya', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': 'Nagoya University Hospital', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '260-8712', 'city': 'Chiba', 'state': 'Chiba', 'country': 'Japan', 'facility': 'National Hospital Organization Chiba-East Hospital', 'geoPoint': {'lat': 35.6, 'lon': 140.11667}}, {'zip': '275-8580', 'city': 'Narashino', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Chiba-ken Saiseikai Narashino Hospital', 'geoPoint': {'lat': 35.68184, 'lon': 140.04152}}, {'zip': '284-0003', 'city': 'Yotukaidou', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Shimoshizu National Hospital'}, {'zip': '810-0001', 'city': 'Fukuoka', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Kondo clinic for rheumatism and orthopaedics', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'zip': '810-8563', 'city': 'Fukuoka', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'National Hospital Organization Kyushu Medical Center', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'zip': '812-0025', 'city': 'Fukuoka', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Medical Co.LTA PS Clinic', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'zip': '820-8505', 'city': 'Iiduka', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Aso Iizuka Hospital'}, {'zip': '807-8555', 'city': 'Kitakyushu', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'University of Occupational and Environmental Health Hospital', 'geoPoint': {'lat': 33.85181, 'lon': 130.85034}}, {'zip': '830-8543', 'city': 'Kurume', 'state': 'Fukuoka', 'country': 'Japan', 'facility': "St. Mary's Hospital", 'geoPoint': {'lat': 33.31667, 'lon': 130.51667}}, {'zip': '814-0002', 'city': 'Sawara-ku', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'SHONO Rheumatism Clinic'}, {'zip': '960-8251', 'city': 'Fukushima', 'state': 'Fukushima', 'country': 'Japan', 'facility': 'Fukusima Daiichi Hospital', 'geoPoint': {'lat': 37.75, 'lon': 140.46667}}, {'zip': '370-0053', 'city': 'Takasaki', 'state': 'Gunma', 'country': 'Japan', 'facility': 'Inoue Hospital', 'geoPoint': {'lat': 36.33333, 'lon': 139.01667}}, {'zip': '739-0002', 'city': 'Higashihiroshima', 'state': 'Hiroshima', 'country': 'Japan', 'facility': 'Higashihiroshima Memorial Hospital', 'geoPoint': {'lat': 34.40861, 'lon': 132.73682}}, {'zip': '730-0017', 'city': 'Hiroshima', 'state': 'Hiroshima', 'country': 'Japan', 'facility': 'Hiroshima Rheumatology Clinic', 'geoPoint': {'lat': 34.4, 'lon': 132.45}}, {'zip': '730-8619', 'city': 'Hiroshima', 'state': 'Hiroshima', 'country': 'Japan', 'facility': 'Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital', 'geoPoint': {'lat': 34.4, 'lon': 132.45}}, {'zip': '078-8243', 'city': 'Asahikawa', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Katayama Orthopedic Rheumatology Clinic', 'geoPoint': {'lat': 43.77063, 'lon': 142.36489}}, {'zip': '060-8604', 'city': 'Sapporo', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Sapporo city general hospital', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'zip': '060-8648', 'city': 'Sapporo', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Hokkaido University Hospital', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'zip': '063-0811', 'city': 'Sapporo', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Hokkaido Medical Center for Rheumatic Diseases', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'zip': '663-8501', 'city': 'Nishinomiya', 'state': 'Hyōgo', 'country': 'Japan', 'facility': 'The Hospital of Hyogo College of Medicine', 'geoPoint': {'lat': 34.71562, 'lon': 135.33199}}, {'zip': '316-0035', 'city': 'Hitachi-shi', 'state': 'Ibaraki', 'country': 'Japan', 'facility': 'Taga General Hospital'}, {'zip': '305-8576', 'city': 'Tsukuba', 'state': 'Ibaraki', 'country': 'Japan', 'facility': 'Tsukuba University Hospital', 'geoPoint': {'lat': 36.08333, 'lon': 140.11667}}, {'zip': '160-8582', 'city': 'Shinjuku-ku, Tokyo', 'state': 'Japan', 'country': 'Japan', 'facility': 'Keio University Hospital', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'zip': '252-0392', 'city': 'Sagamihara', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'National Hospital Organization Sagamihara National Hospital', 'geoPoint': {'lat': 35.56707, 'lon': 139.24167}}, {'zip': '861-1196', 'city': 'Koushi', 'state': 'Kumamoto', 'country': 'Japan', 'facility': 'Kumamoto Saishunso National Hospital'}, {'zip': '862-0976', 'city': 'Kumamoto', 'state': 'Kumamoto', 'country': 'Japan', 'facility': 'Kumamoto Orthopaedic Hospital', 'geoPoint': {'lat': 32.80589, 'lon': 130.69181}}, {'zip': '602-8566', 'city': 'Kyoto', 'state': 'Kyoto', 'country': 'Japan', 'facility': 'University Hospital, Kyoto Prefectural University of Medicine', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'zip': '606-8507', 'city': 'Kyoto', 'state': 'Kyoto', 'country': 'Japan', 'facility': 'Kyoto University Hospital', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'zip': '514-1101', 'city': 'Tsu', 'state': 'Mie-ken', 'country': 'Japan', 'facility': 'National hospital Organization Mie Chuou Medical Center', 'geoPoint': {'lat': 34.73333, 'lon': 136.51667}}, {'zip': '983-0833', 'city': 'Sendai', 'state': 'Miyagi', 'country': 'Japan', 'facility': 'Hikarigaoka Spellman Hospital', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}, {'zip': '852-8501', 'city': 'Nagasaki', 'state': 'Nagasaki', 'country': 'Japan', 'facility': 'Nagasaki University Hospital of Medicine and Dentistry', 'geoPoint': {'lat': 32.75, 'lon': 129.88333}}, {'zip': '856-0835', 'city': 'Ohmura', 'state': 'Nagasaki', 'country': 'Japan', 'facility': 'National Hospital Organization Nagasaki Medical Center'}, {'zip': '857-1195', 'city': 'Sasebo', 'state': 'Nagasaki', 'country': 'Japan', 'facility': 'Sasebo Chuo Hospital', 'geoPoint': {'lat': 33.16834, 'lon': 129.72502}}, {'zip': '634-0007', 'city': 'Kashihara', 'state': 'Nara', 'country': 'Japan', 'facility': 'Higami hospital', 'geoPoint': {'lat': 33.95, 'lon': 135.78333}}, {'zip': '951-8520', 'city': 'Niigata', 'state': 'Niigata', 'country': 'Japan', 'facility': 'Niigata University Medical & Dental Hospital', 'geoPoint': {'lat': 37.92259, 'lon': 139.04125}}, {'zip': '870-0823', 'city': 'Ōita', 'state': 'Oita Prefecture', 'country': 'Japan', 'facility': 'A Medical Corporation Oribe Rheumatism Internist Clinic', 'geoPoint': {'lat': 33.23333, 'lon': 131.6}}, {'zip': '586-8521', 'city': 'Kawachi-Nagano', 'state': 'Osaka', 'country': 'Japan', 'facility': 'National Hospital Organization Osaka Minami Center', 'geoPoint': {'lat': 34.44108, 'lon': 135.58283}}, {'zip': '530-8480', 'city': 'Osaka', 'state': 'Osaka', 'country': 'Japan', 'facility': 'The Tazuke Kofukai Medical Research Institute Kitano Hospital', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'zip': '843-0393', 'city': 'Ureshino', 'state': 'Saga-ken', 'country': 'Japan', 'facility': 'Ureshino Medical Center', 'geoPoint': {'lat': 33.13525, 'lon': 130.05718}}, {'zip': '350-8550', 'city': 'Kawagoe-shi', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Saitama Medical Center'}, {'zip': '364-8501', 'city': 'Kitamoto', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Kitasato University Kitasato Institute Medical Center Hospital', 'geoPoint': {'lat': 36.03322, 'lon': 139.53775}}, {'zip': '336-8522', 'city': 'Saitama', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Saitama city hospital', 'geoPoint': {'lat': 35.90807, 'lon': 139.65657}}, {'zip': '430-8558', 'city': 'Hamamatsu', 'state': 'Shizuoka', 'country': 'Japan', 'facility': 'Seirei Hamamatsu General Hospital', 'geoPoint': {'lat': 34.7, 'lon': 137.73333}}, {'zip': '116-8567', 'city': 'Arakawa-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': "Tokyo Women's Medical University Medical Center East"}, {'zip': '113-8431', 'city': 'Bunkyo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Juntendo University Hospital'}, {'zip': '113-8519', 'city': 'Bunkyo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Tokyo Medical And Dental University Hospital, Faculty of Medicine'}, {'zip': '113-8655', 'city': 'Bunkyo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'The University of Tokyo Hospital'}, {'zip': '101-0062', 'city': 'Chiyoda-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Sasaki Foundation Kyoundo Hospital'}, {'zip': '136-0075', 'city': 'Koto-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Juntendo Tokyo Koto Geriatric Medical Center'}, {'zip': '152-8902', 'city': 'Meguro-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'National Hospital Organization Tokyo Medical Center'}, {'zip': '208-0011', 'city': 'Musashimurayama-shi', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'National Hospital Organization MURAYAMA Medical Center'}, {'zip': '155-0031', 'city': 'Setagaya-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Fukuhara Hospital'}, {'zip': '162-0054', 'city': 'Shinjyuku-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': "Tokyo Women's Medical University, Institute of Rheumatology"}, {'zip': '982-0032', 'city': 'Miyagi', 'country': 'Japan', 'facility': 'Sendai Taihaku Hospital', 'geoPoint': {'lat': 26.62566, 'lon': 128.18236}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}